

FILE 'HOME' ENTERED AT 19:03:42 ON 26 APR  
1998

=> index bioscience

COST IN U.S. DOLLARS  
SINCE FILE TOTAL

ENTRY SESSION  
FULL ESTIMATED COST  
0.15 0.15

INDEX 'AGRICOLA, AIDSLINE, ANABSTR, AQUASCI,  
BIOBUSINESS, BIOSIS, BIOTECHABS,  
BIOTECHDS, CABA, CANCERLIT, CAPLUS,  
CEABA, CEN, CIN, CJACS, CONFSCI,  
CROPB, CROPU, DDFB, DDFU, DGENE,  
DISSABS, DRUGB, DRUGLAUNCH, DRUGNL,  
DRUGU, EMBAL, EMBASE, ESTA, GENBANK,  
...' ENTERED AT 19:03:54 ON 26 APR 1998

49 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term  
postings or to view  
search error messages that display as 0\* with  
SET DETAIL OFF.

=> s igf? or (insulin?(3a) (growth factor?))

```
954  FILE AGRICOLA
  90  FILE AIDSLINE
   36  FILE ANABSTR
 127  FILE AQUASCI
1014  FILE BIOBUSINESS
22432 FILE BIOSIS
   517 FILE BIOTECHABS
   517 FILE BIOTECHDS
 8 FILES SEARCHED...
 2548  FILE CABA
 6500  FILE CANCERLIT
10 FILES SEARCHED...
 15486 FILE CAPLUS
   163  FILE CEABA
    15  FILE CEN
   130  FILE CIN
   253  FILE CJACS
   845  FILE CONFSCI
     5  FILE CROPUL
   139  FILE DDFB
 1818  FILE DDFU
 1289  FILE DGENE
```

```
21 FILES SEARCHED...
    750  FILE DISSABS
    139  FILE DRUGB
      73  FILE DRUGNL
   2281  FILE DRUGU
   266  FILE EMBAL
 14107  FILE EMBASE
      50  FILE FSTA
 13936  FILE GENBANK
      6  FILE HEALSAFE
21 FILES SEARCHED...
```

31 FILES SEARCHED...

813	FILE	IFIPAT
1416	FILE	JICST-EPLUS
19	FILE	KOSMET
4394	FILE	LIFESCI
16989	FILE	MEDLINE

36 FILES SEARCHED...  
23 FILE NIOSHTIC  
84 FILE NTIS  
28 FILE OCEAN

```
38    FILE PHAR
      3    FILE PHIC
    297   FILE PHIN
    749   FILE PROMT
  16541  FILE SCISEARCH
44 FILES SEARCHED...
  2354   FILE TOXLINE
10021   FILE TOXLIT
  3150   FILE USPATFULL
  2223   FILE WPIDS
  2223   FILE WPINDEX
```

47 FILES HAVE ONE OR MORE ANSWERS, 49  
FILES SEARCHED IN STNINDEX

L1 QUE IGF? OR (INSULIN? (3A) (GROWTH  
FACTOR?))

=> s 11 and stroke?

5 FILE BIOBUSINESS  
24 FILE BIOSIS  
2 FILE BIOTECHABS  
2 FILE BIOTECHDS  
4 FILE CANCERLIT

10 FILES SEARCHED...

24	FILE	CAPLUS
2	FILE	CEABA
3	FILE	CEN
1	FILE	CIN
11	FILE	CJACS
8	FILE	DDFU
66	FILE	DGENE
2	FILE	DISSABS
6	FILE	DRUGNL
17	FILE	DRUGU
1	FILE	EMBAL
19	FILE	EMBASE

```
28 FILES SEARCHED...
      3  FILE IFIPAT
      2  FILE LIFESCI
     22  FILE MEDLINE
38 FILES SEARCHED...
      1  FILE PHAR
     22  FILE PHIN
     33  FILE PROMT
     15  FILE SCISEARCH
      5  FILE TOXLINE
     12  FILE TOXLIT
    116  FILE USPATFULL
      9  FILE WPIDS
      9  FILE WPINDEX
```

29 FILES HAVE ONE OR MORE ANSWERS, 49  
FILES SEARCHED IN STNINDEX

L2      QUE L1 AND STROKE?

=> s 11 and (cns? or brain? or  
(central?(3a)(neur? or nerv?)))

```
15   FILE AGRICOLA
     1   FILE ANABSTR
     11  FILE AQUASCI
     14  FILE BIOBUSINESS
1006  FILE BIOSIS
6 FILES SEARCHED...
13   FILE BIOTECHABS
13   FILE BIOTECHDS
67   FILE CABA
294  FILE CANCERLIT
10 FILES SEARCHED...
933  FILE CAPLUS
     8   FILE CEABA
```

2 FILE CEN  
 7 FILE CIN  
 45 FILE CJACS  
 11 FILE CONFSCI  
 3 FILE DDFB  
 28 FILE DDFU  
 23 FILE DGENE  
 70 FILE DISSABS  
 22 FILES SEARCHED...  
 3 FILE DRUGB  
 41 FILE DRUGNL  
 51 FILE DRUGU  
 13 FILE EMBAL  
 1022 FILE EMBASE  
 28 FILES SEARCHED...  
 1 FILE FSTA  
 89 FILE GENBANK  
 23 FILE IFIPAT  
 80 FILE JICST-EPLUS  
 33 FILES SEARCHED...  
 294 FILE LIFESCI  
 894 FILE MEDLINE  
 36 FILES SEARCHED...  
 3 FILE OCEAN  
 2 FILE PHAR  
 1 FILE PHIC  
 41 FILE PHIN  
 112 FILE PROMT  
 893 FILE SCISEARCH  
 44 FILES SEARCHED...  
 114 FILE TOXLINE  
 519 FILE TOXLIT  
 46 FILES SEARCHED...  
 552 FILE USPATFULL  
 31 FILE WPIDS  
 31 FILE WPINDEX  
 41 FILES HAVE ONE OR MORE ANSWERS, 49  
 FILES SEARCHED IN STNINDEX  
 L3 QUE L1 AND (CNS? OR BRAIN? OR  
 (CENTRAL?(3A)(NEUR? OR NERV?)))  
 => s 13 and (stroke? or trauma?)  
 2 FILE BIOBUSINESS  
 19 FILE BIOSIS  
 6 FILES SEARCHED...  
 1 FILE BIOTECHABS  
 1 FILE BIOTECHDS  
 2 FILE CANCERLIT  
 10 FILES SEARCHED...  
 37 FILE CAPLUS  
 2 FILE CEABA  
 1 FILE CEN  
 1 FILE CIN  
 6 FILE CJACS  
 1 FILE DGENE  
 3 FILE DISSABS  
 22 FILES SEARCHED...  
 7 FILE DRUGNL  
 1 FILE DRUGU  
 2 FILE EMBAL  
 20 FILE EMBASE  
 28 FILES SEARCHED...  
 6 FILE IFIPAT  
 5 FILE LIFESCI  
 35 FILES SEARCHED...  
 16 FILE MEDLINE  
 36 FILES SEARCHED...  
 1 FILE PHAR  
 13 FILE PHIN  
 25 FILE PROMT  
 21 FILE SCISEARCH  
 44 FILES SEARCHED...  
 2 FILE TOXLINE  
 6 FILE TOXLIT  
 46 FILES SEARCHED...  
 150 FILE USPATFULL  
 12 FILE WPIDS  
 12 FILE WPINDEX  
 28 FILES HAVE ONE OR MORE ANSWERS, 49  
 FILES SEARCHED IN STNINDEX  
 L4 QUE L3 AND (STROKE? OR TRAUMA?)  
 => file uspatfull  
 COST IN U.S. DOLLARS  
 SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST  
 37.80 37.95  
 FILE 'USPATFULL' ENTERED AT 19:54:06 ON 26  
 APR 1998  
 CA INDEXING COPYRIGHT (C) 1998 AMERICAN  
 CHEMICAL SOCIETY (ACS)  
 FILE COVERS 1971 TO PATENT PUBLICATION DATE:  
 21 Apr 1998 (19980421/PD)  
 FILE LAST UPDATED: 22 Apr 1998 (19980422/ED)  
 HIGHEST PATENT NUMBER: US5742935  
 CA INDEXING IS CURRENT THROUGH 22 Apr 1998  
 (19980422/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH:  
 21 Apr 1998 (19980421/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED:  
 JAN 1998  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS  
 ISSUE DATE: Feb 1998  
 => s 14  
 2502 IGF?  
 9480 INSULIN?  
 133294 GROWTH  
 409226 FACTOR?  
 8291 GROWTH FACTOR?  
 (GROWTH(W) FACTOR?)  
 1301 INSULIN?(3A) (GROWTH FACTOR?)  
 4487 CNS?  
 21405 BRAIN?  
 632703 CENTRAL?  
 25591 NEUR?  
 23797 NERV?  
 10873 CENTRAL?(3A)(NEUR? OR NERV?)  
 112338 STROKE?  
 15512 TRAUMA?  
 L5 150 L3 AND (STROKE? OR TRAUMA?)  
 => d 140-150  
 L5 ANSWER 140 OF 150 USPATFULL  
 AN 92:84854 USPATFULL  
 TI Method for potentiation of a  
 therapeutic agent  
 IN Garcia y Bellon, Donato P., Ponciano  
 Arriaga #28 PB, Col. Centro,  
 Cuauhtemoc, Mexico 06030  
 Garcia, Jr., Donato P., 4558 Blvd.  
 Agua Cliente Col. Aviacion,  
 Tijuana, Mexico 22420  
 Ayre, Steven G., 483 First St.,  
 Antioch, IL, United States 60002  
 PI US 5155096 921013  
 AI US 90-615621 901119 (7)

RLI Continuation-in-part of Ser. No. US  
87-77833, filed on 27 Jul  
1987, now patented, Pat. No. US  
4971951

DT Utility

LN.CNT 978

INCL INCLM: 514/003.000  
INCLS: 514/004.000; 514/825.000;  
514/885.000; 514/886.000;  
514/893.000; 514/966.000;  
514/967.000  
NCL NCLM: 514/003.000  
NCLS: 514/004.000; 514/825.000;  
514/885.000; 514/886.000;  
514/893.000; 514/966.000;  
514/967.000  
IC [5]  
ICM: A61K037-26  
EXF 514/3; 514/4; 424/825; 424/885;  
424/886; 424/893; 424/966; 424/967  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 141 OF 150 USPATFULL  
AN 92:84797 USPATFULL  
TI Use of thrombospondin to promote wound  
healing  
IN Eyal, Jacob, Baltimore, MD, United  
States  
Tuszynski, George, Mays Landing, NJ,  
United States  
PA W. R. Grace & Co.-Conn., New York, NY,  
United States (U.S.  
corporation)  
Medical College of Pennsylvania,  
Philadelphia, PA, United States  
(U.S. corporation)  
PI US 5155038 921013  
AI US 90-483500 900222 (7)  
DT Utility  
LN.CNT 353  
INCL INCLM: 435/240.200  
INCLS: 514/008.000; 435/070.210;  
424/077.000  
NCL NCLM: 514/008.000  
NCLS: 424/077.000; 435/070.210  
IC [5]  
ICM: C12P021-02  
ICS: C12N005-00; A01N025-24; A61K037-  
10  
EXF 514/8; 435/70.21; 435/240.2; 424/77  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 142 OF 150 USPATFULL  
AN 92:82339 USPATFULL  
TI System for diagnosis and treatment of  
wounds  
IN Eriksson, Elof, Boston, MA, United  
States  
PA Brigham and Women's Hospital, Boston,  
MA, United States (U.S.  
corporation)  
PI US 5152757 921006  
AI US 91-707248 910522 (7)  
RLI Continuation of Ser. No. US 89-451957,  
filed on 14 Dec 1989, now  
abandoned  
DT Utility  
LN.CNT 1211  
INCL INCLM: 604/305.000  
NCL NCLM: 604/305.000  
IC [5]  
ICM: A61F013-00  
EXF 604/304-308; 424/DIG.13; 623/15;  
128/369; 128/370  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 143 OF 150 USPATFULL  
AN 92:40820 USPATFULL  
TI Amphiregulin: a bifunctional growth  
modulating glycoprotein  
IN Shoyab, Mohammed, Seattle, WA, United  
States  
McDonald, Vicki L., Kent, WA, United  
States  
Bradley, James G., Woodinville, WA,  
United States  
Plowman, Gregory D., Seattle, WA,  
United States  
PA Oncogen, Seattle, WA, United States  
(U.S. corporation)  
PI US 5115096 920519  
AI US 89-297816 890117 (7)  
RLI Continuation-in-part of Ser. No. US  
88-181884, filed on 15 Apr  
1988, now abandoned which is a  
continuation-in-part of Ser. No. US  
88-148327, filed on 25 Jan 1988, now  
abandoned  
DT Utility  
LN.CNT 2689  
INCL INCLM: 530/322.000  
INCLS: 530/324.000  
NCL NCLM: 530/322.000  
NCLS: 530/324.000  
IC [5]  
ICM: C07K009-00  
EXF 530/322  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 144 OF 150 USPATFULL  
AN 92:35989 USPATFULL  
TI Processes for producing collagen  
matrixes and methods of using  
same  
IN Chu, George H., Sunnyvale, CA, United  
States  
Ogawa, Yasushi, Pacifica, CA, United  
States  
McPherson, John M., Framingham, MA,  
United States  
Ksander, George, Redwood City, CA,  
United States  
Pratt, Bruce, Union City, CA, United  
States  
Hendricks, Diana, Brea, CA, United  
States  
McMullin, Hugh, San Bruno, CA, United  
States  
PA Collagen Corporation, Palo Alto, CA,  
United States (U.S.  
corporation)  
PI US 5110604 920505  
AI US 90-630299 901219 (7)  
RLI Division of Ser. No. US 88-213726,  
filed on 30 Jun 1988, now  
patented, Pat. No. US 5024841  
DT Utility  
LN.CNT 711  
INCL INCLM: 424/484.000  
INCLS: 424/422.000; 424/085.200;  
424/085.400; 514/801.000;  
530/356.000; 530/399.000;  
604/890.100  
NCL NCLM: 424/484.000  
NCLS: 128/DIG.008; 424/085.200;  
424/085.400; 424/422.000;  
514/801.000; 530/356.000;  
530/399.000; 604/890.100;  
623/011.000  
IC [5]

ICM: A61K009-14  
ICS: A61K037-66; A61K037-12; A61K037-24  
EXF 424/422-426; 424/444; 424/484;  
424/85.2; 424/85.4; 623/16;  
514/801; 514/56; 530/356; 530/399;  
604/890.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 145 OF 150 USPATFULL  
AN 92:17110 USPATFULL  
TI Treating disorders by application of  
insulin-like  
growth factor  
IN Lewis, Michael E., Landenberg, PA,  
United States  
Kauer, James C., Kennett Square, PA,  
United States  
Smith, Kevin R., Downingtown, PA,  
United States  
Callison, Kathleen V., Merchantville,  
NJ, United States  
Baldino, Jr., Frank, Landenberg, PA,  
United States  
PA Cephalon, Inc., West Chester, PA,  
United States (U.S. corporation)  
PI US 5093317 920303  
AI US 89-361595 890605 (7)  
DT Utility  
LN.CNT 858  
INCL INCLM: 514/012.000  
INCLS: 514/003.000; 514/004.000;  
514/885.000; 514/903.000;  
514/021.000; 424/556.000;  
424/570.000  
NCL NCLM: 514/012.000  
NCLS: 424/556.000; 424/570.000;  
514/003.000; 514/004.000;  
514/021.000; 514/885.000;  
514/903.000  
IC [5]  
ICM: A61K037-36  
ICS: A61K037-26  
EXF 424/98; 424/556; 424/570; 514/3;  
514/4; 514/12; 514/21; 514/885;  
514/903  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 146 OF 150 USPATFULL  
AN 91:84437 USPATFULL  
TI Method for preventing tissue damage  
after an ischemic episode  
IN Sheffield, Warren D., Lebanon, NJ,  
United States  
PA Ethicon, Inc., Somerville, NJ, United  
States (U.S. corporation)  
PI US 5057494 911015  
AI US 88-227579 880803 (7)  
DT Utility  
LN.CNT 487  
INCL INCLM: 514/012.000  
INCLS: 514/021.000  
NCL NCLM: 514/012.000  
NCLS: 514/021.000  
IC [5]  
ICM: A61K037-02  
ICS: A61K037-36  
EXF 514/12; 514/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 147 OF 150 USPATFULL  
AN 91:48454 USPATFULL  
TI Collagen wound healing matrices and  
process for their production

IN Chu, George H., Sunnyvale, CA, United  
States  
Ogawa, Yasushi, Pacifica, CA, United  
States  
McPherson, John M., Hopkinton, MA,  
United States  
Ksander, George, Redwood City, CA,  
United States  
Pratt, Bruce, Union City, CA, United  
States  
Hendricks, Diana, Brea, CA, United  
States  
McMullin, Hugh, San Bruno, CA, United  
States  
PA Collagen Corporation, Palo Alto, CA,  
United States (U.S.  
corporation)  
PI US 5024841 910618  
AI US 88-213726 880630 (7)  
DT Utility  
LN.CNT 759  
INCL INCLM: 424/422.000  
INCLS: 424/484.000; 424/085.200;  
424/085.400; 424/426.000;  
530/356.000; 530/399.000;  
514/056.000; 514/801.000;  
604/890.100  
NCL NCLM: 424/422.000  
NCLS: 128/DIG.008; 424/085.200;  
424/085.400; 424/426.000;  
424/484.000; 514/056.000;  
514/801.000; 530/356.000;  
530/399.000; 604/890.100;  
623/011.000  
IC [5]  
ICM: A61F013-00  
ICS: A61K009-14; A61K037-12; A61K031-  
725  
EXF 424/422-426; 424/444; 424/484;  
424/85.2; 424/85.4; 623/16;  
514/801; 514/56; 530/356; 530/399;  
604/890.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 148 OF 150 USPATFULL  
AN 88:441 USPATFULL  
TI Apparatus and method for adjusting  
heart/pacer rate relative to  
cardiac pCO<sub>2</sub> to obtain a required  
cardiac output  
IN Koning, Gerrit, Vries, Netherlands  
Schroepel, Edward A., Miamar, FL,  
United States  
PA Teletronics N.V., Curacao,  
Netherlands Antilles (non-U.S.  
corporation)  
PI US 4716887 880105  
AI US 85-722575 850411 (6)  
DT Utility  
LN.CNT 946  
INCL INCLM: 128/419.000PG  
INCLS: 128/635.000  
NCL NCLM: 607/024.000  
NCLS: 600/353.000; 607/016.000;  
607/022.000  
IC [4]  
ICM: A61N001-36  
EXF 128/635; 128/2; 128/419PG

L5 ANSWER 149 OF 150 USPATFULL  
AN 87:82990 USPATFULL  
TI Novel phosphotyrosyl protein  
phosphatase  
IN Liang, Theming, Miami, FL, United  
States

Slater, Eve E., Short Hills, NJ,  
 United States  
 PA Merck & Co., Inc., Rahway, NJ, United  
 States (U.S. corporation)  
 PI US 4710469 871201  
 AI US 86-858622 860502 (6)  
 DT Utility  
 LN.CNT 638  
 INCL INCLM: 435/194.000  
 INCLS: 530/352.000  
 NCL NCLM: 435/194.000  
 NCLS: 530/352.000  
 IC [4]  
 ICM: C12N009-12  
 EXF 435/194; 530/352  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 150 OF 150 USPATFULL  
 AN 87:74975 USPATFULL  
 TI DNA sequences encoding erythropoietin  
 IN Lin, Fu-Kuen, Thousand Oaks, CA,  
 United States  
 PA Kiren-Amgen, Inc., Thousand Oaks, CA,  
 United States (U.S.  
 corporation)  
 PI US 4703008 871027  
 AI US 84-675298 841130 (6)  
 RLI Continuation-in-part of Ser. No. US  
 83-561024, filed on 13 Dec  
 1983, now abandoned And a  
 continuation-in-part of Ser. No. US  
 84-582185, filed on 21 Feb 1984, now  
 abandoned And a  
 continuation-in-part of Ser. No. US  
 84-655841, filed on 28 Sep  
 1984  
 DT Utility  
 LN.CNT 2313  
 INCL INCLM: 435/240.200  
 INCLS: 435/172.300; 435/253.000;  
 435/006.000; 435/317.000;  
 435/320.000; 536/027.000;  
 935/009.000; 935/010.000;  
 935/013.000; 935/079.000;  
 935/080.000  
 NCL NCLM: 435/360.000  
 NCLS: 435/006.000; 435/172.300;  
 435/252.300; 435/252.330;  
 435/320.100; 435/365.100;  
 536/023.510; 536/023.720;  
 536/024.100; 536/024.300;  
 536/024.310; 536/025.320;  
 930/090.000; 935/009.000;  
 935/010.000; 935/013.000;  
 935/079.000; 935/080.000  
 IC [4]  
 ICM: C12N005-00  
 ICS: C12N015-00; C12N001-20; C12N001-  
 00; C12Q001-68; C07H015-12  
 EXF 435/68; 435/317; 435/172.3; 435/253;  
 435/240; 935/6; 935/10;  
 935/11; 935/27; 935/69; 935/73; 935/13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 150 kwic

L5 ANSWER 150 OF 150 USPATFULL  
 DETD . . . plates containing 50  
 micrograms/ml Ampicillin. GeneScreen  
 filters (New England Nuclear Catalog  
 No. NEF-972) were pre-wet on  
 a BHI-CAM plate (Bacto brain heart  
 infusion 37 g/L,

Casamino acids 2 g/L and agar 15 g/L,  
 containing 500 micrograms/ml  
 Chloramphenicol) and were used to. . .  
 .  
 DETD . . . Included within the class of  
 humans treatable with  
 products of the invention are patients  
 generally requiring blood  
 transfusions and including **trauma**  
 victims, surgical  
 patients, renal disease patients  
 including dialysis patients, and  
 patients with a variety of blood  
 composition affecting disorders,  
 such. . .  
 DETD . . . use in compositions of the  
 invention include compounds  
 independently noted for erythropoietic  
 stimulatory effects, such  
 as testosterone, progenitor cell  
 stimulators, **insulin**  
 -like **growth factor**, prostaglandins,  
 serotonin, cyclic AMP, prolactin and  
 triiodothyronine, as well as  
 agents generally employed in treatment  
 of aplastic anemia, such  
 as. . .

=> s 13 and (stroke?)

2502 IGF?  
 9480 INSULIN?  
 133294 GROWTH  
 409226 FACTOR?  
 8291 GROWTH FACTOR?  
 (GROWTH(W) FACTOR?)  
 1301 INSULIN?(3A) (GROWTH FACTOR?)  
 4487 CNS?  
 21405 BRAIN?  
 632703 CENTRAL?  
 25591 NEUR?  
 23797 NERV?  
 10873 CENTRAL?(3A)(NEUR? OR NERV?)  
 112338 STROKE?

L6 73 L3 AND (STROKE?)

=> d 60-73

L6 ANSWER 60 OF 73 USPATFULL  
 AN 96:20903 USPATFULL  
 TI Composition useful for in vivo  
 delivery of biologics and methods  
 employing same  
 IN Grinstaff, Mark W., Pasadena, CA,  
 United States  
 Soon-Shiong, Patrick, Los Angeles, CA,  
 United States  
 Wong, Michael, Champaign, IL, United  
 States  
 Sandford, Paul A., Los Angeles, CA,  
 United States  
 Suslick, Kenneth S., Champaign, IL,  
 United States  
 Desai, Neil P., Los Angeles, CA,  
 United States  
 PA Vivorx Pharmaceuticals, Inc., Santa  
 Monica, CA, United States  
 (U.S. corporation)  
 PI US 5498421 960312  
 AI US 94-200235 940222 (8)  
 RLI Continuation-in-part of Ser. No. US  
 93-23698, filed on 22 Feb

1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 93-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478

DT Utility  
LN.CNT 3321  
INCL INCLM: 424/450.000  
INCLS: 424/451.000; 424/455.000;  
424/009.300; 424/009.340;  
424/009.370; 424/009.400;  
424/009.500  
NCL NCLM: 424/450.000  
NCLS: 424/009.300; 424/009.340;  
424/009.370; 424/009.400;  
424/009.500; 424/451.000;  
424/455.000  
IC [6]  
ICM: A61K037-22  
ICS: A61K009-127  
EXF 424/451; 424/45; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 61 OF 73 USPATFULL  
AN 96:9366 USPATFULL  
TI Glucose-regulated promoter of yeast acetyl-CoA hydrolase  
IN Smith, John A., Scotch Plains, NJ, United States  
Lee, Fang-Jen S., North Bethesda, MD, United States  
Lin, Lee-Wen, North Bethesda, MD, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)  
PI US 5487990 960130  
AI US 92-921796 920730 (7)  
RLI Continuation-in-part of Ser. No. US 90-480452, filed on 15 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 88-213943, filed on 1 Jul 1988, now abandoned And a continuation-in-part of Ser. No. US 89-297003, filed on 13 Jan 1989, now abandoned  
DT Utility  
LN.CNT 2244  
INCL INCLM: 435/172.300  
INCLS: 435/254.200; 435/254.210;  
435/254.220; 435/254.230;  
435/320.100; 536/024.100;  
935/037.000; 935/069.000;  
530/371.000  
NCL NCLM: 435/172.300  
NCLS: 435/254.200; 435/254.210;  
435/254.220; 435/254.230;  
435/320.100; 530/371.000;  
536/024.100; 935/037.000;  
935/069.000  
IC [6]  
ICM: C12N001-19  
ICS: C12N015-81; C12N015-11  
EXF 536/24.1; 530/371; 435/320.1;  
435/254.2; 435/254.21; 435/254.22;  
435/254.23; 435/172.3; 935/37; 935/69  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 62 OF 73 USPATFULL  
AN 95:110557 USPATFULL  
TI Fused Pyrrolocarbazoles  
IN Hudkins, Robert L., Chester Springs, PA, United States

Knight, Jr., Ernest, Wilmington, DE, United States  
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)  
PI US 5475110 951212  
AI US 94-323755 941014 (8)  
DT Utility  
LN.CNT 2781  
INCL INCLM: 546/256.000  
INCLS: 546/271.000; 548/417.000  
NCL NCLM: 546/256.000  
NCLS: 536/017.400; 546/022.000;  
546/276.700; 548/416.000;  
548/417.000; 548/418.000;  
548/469.000  
IC [6]  
ICM: C07D487-06  
EXF 548/417; 546/256; 546/271  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 63 OF 73 USPATFULL  
AN 95:64902 USPATFULL  
TI Neuropeptide antagonists  
IN Rozengurt, Enrique, London, England  
Woll, Penella, London, England  
PA Imperial Cancer Research Technology, Ltd., London, England (non-U.S. corporation)  
PI US 5434132 950718  
AI US 93-147896 931102 (8)  
RLI Continuation of Ser. No. US 92-994443, filed on 23 Dec 1992 which is a continuation of Ser. No. US 90-573158, filed on 19 Oct 1990, now abandoned  
PRAI GB 88-664 880321  
DT Utility  
LN.CNT 1192  
INCL INCLM: 514/002.000  
INCLS: 530/329.000; 530/314.000;  
530/315.000  
NCL NCLM: 514/002.000  
NCLS: 530/314.000; 530/315.000;  
530/329.000  
IC [6]  
ICM: A61K038-08  
ICS: A61K038-11; A61K038-16; C07K011-00  
EXF 424/198.1; 530/326; 530/327; 530/328;  
530/329; 514/2; 514/314;  
514/315  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 73 USPATFULL  
AN 95:64843 USPATFULL  
TI Fibrinolytic and anti-thrombotic cleavable dimers  
IN Dawson, Keith, Marlow, United Kingdom  
Hunter, Michael G., Aylesbury, United Kingdom  
Czaplewski, Lloyd G., Didcot, United Kingdom  
PA British Bio-Technology Limited, Oxford, England (non-U.S. corporation)  
PI US 5434073 950718  
WO 9109125 910627  
AI US 92-854596 920603 (7)  
WO 90-GB1911 901207  
920603 PCT 371 date  
920603 PCT 102(e) date  
PRAI GB 89-27722 891207  
DT Utility  
LN.CNT 2191  
INCL INCLM: 435/216.000

INCLS: 530/350.000; 530/402.000;  
435/069.700; 424/094.640  
NCL NCLM: 435/216.000  
NCLS: 424/094.640; 435/069.700;  
530/350.000; 530/402.000  
IC [6]  
ICM: C12N009-70  
ICS: C07K013-00  
EXF 435/69.7; 435/216; 530/402; 530/350;  
424/94.64  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 73 USPATFULL  
AN 94:80075 USPATFULL  
TI Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders  
IN Roy, Soumitra, San Francisco, CA, United States  
Vehar, Gordon A., San Carlos, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5346991 940913  
AI US 91-714819 910613 (7)  
DT Utility  
LN.CNT 2407  
INCL INCLM: 530/350.000  
INCLS: 530/381.000; 530/829.000;  
435/172.300  
NCL NCLM: 530/350.000  
NCLS: 435/172.300; 530/381.000;  
530/829.000  
IC [5]  
ICM: C07K013-00  
ICS: C12N015-12; A61K037-02  
EXF 435/172.1; 435/172.3; 530/350;  
530/381; 530/829; 514/822  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 73 USPATFULL  
AN 94:62555 USPATFULL  
TI Purified active somatostatin receptor  
IN Eppler, Cecil M., Langhorne, PA, United States  
Zysk, John R., Frenchtown, NJ, United States  
Corbett, Martin J., Mt. Holly, NJ, United States  
Shieh, Hong-Ming, Langhorne, PA, United States  
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)  
PI US 5331094 940719  
AI US 92-963246 921019 (7)  
RLI Continuation of Ser. No. US 91-677009, filed on 28 Mar 1991, now abandoned  
DT Utility  
LN.CNT 1080  
INCL INCLM: 530/395.000  
INCLS: 530/350.000  
NCL NCLM: 530/395.000  
NCLS: 530/350.000  
IC [5]  
ICM: C07K015-06  
ICS: C07K015-14  
EXF 530/350; 530/395  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 67 OF 73 USPATFULL  
AN 93:54857 USPATFULL

TI Receptors method for purification of G protein-linked  
IN Eppler, Cecil M., Langhorne, PA, United States  
Shieh, Hong-Ming, Langhorne, PA, United States  
Zysk, John R., Frenchtown, NJ, United States  
Corbett, Martin J., Pemberton, NJ, United States  
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)  
PI US 5225543 930706  
AI US 91-677003 910328 (7)  
DT Utility  
LN.CNT 1336  
INCL INCLM: 530/413.000  
INCLS: 530/395.000; 530/412.000;  
530/415.000  
NCL NCLM: 530/413.000  
NCLS: 530/395.000; 530/412.000;  
530/415.000  
IC [5]  
ICM: C07K003-20  
ICS: C07K003-12; C07K003-18; C07K003-28  
EXF 530/307; 530/311; 530/350; 530/367;  
530/387; 530/412; 530/413;  
530/415  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 73 USPATFULL  
AN 93:6941 USPATFULL  
TI Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates  
IN Friden, Phillip M., Bedford, MA, United States  
PA Alkermes, Inc., Cambridge, MA, United States (U.S. corporation)  
PI US 5182107 930126  
AI US 92-846830 920306 (7)  
RLI Continuation-in-part of Ser. No. US 89-404089, filed on 7 Sep 1989  
DT Utility  
LN.CNT 1327  
INCL INCLM: 424/085.910  
INCLS: 424/085.800; 424/094.100;  
530/387.300; 530/391.100;  
530/391.700; 530/391.900;  
530/399.000; 530/388.220;  
514/021.000  
NCL NCLM: 424/179.100  
NCLS: 424/094.100; 424/143.100;  
424/178.100; 514/021.000;  
530/387.300; 530/388.220;  
530/391.100; 530/391.700;  
530/391.900; 530/399.000  
IC [5]  
ICM: A61K039-44  
ICS: A61K037-36; C07K017-02; C07K015-28  
EXF 530/391.1; 530/391.7; 530/391.9;  
530/387.3; 530/399; 530/388.22;  
424/85.91; 424/85.8; 424/94.1; 514/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 69 OF 73 USPATFULL  
AN 92:84797 USPATFULL  
TI Use of thrombospondin to promote wound healing  
IN Eyal, Jacob, Baltimore, MD, United States

Tuszynski, George, Mays Landing, NJ,  
 United States  
 PA W. R. Grace & Co.-Conn., New York, NY,  
 United States (U.S.  
 corporation)  
 Medical College of Pennsylvania,  
 Philadelphia, PA, United States  
 (U.S. corporation)  
 PI US 5155038 921013  
 AI US 90-483500 900222 (7)  
 DT Utility  
 LN.CNT 353  
 INCL INCLM: 435/240.200  
 INCLS: 514/008.000; 435/070.210;  
 424/077.000  
 NCL NCLM: 514/008.000  
 NCLS: 424/077.000; 435/070.210  
 IC [5]  
 ICM: C12P021-02  
 ICS: C12N005-00; A01N025-24; A61K037-  
 10  
 EXF 514/8; 435/70.21; 435/240.2; 424/77  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
 L6 ANSWER 70 OF 73 USPATFULL  
 AN 92:17110 USPATFULL  
 TI Treating disorders by application of  
 insulin-like  
 growth factor  
 IN Lewis, Michael E., Landenberg, PA,  
 United States  
 Kauer, James C., Kennett Square, PA,  
 United States  
 Smith, Kevin R., Downingtown, PA,  
 United States  
 Callison, Kathleen V., Merchantville,  
 NJ, United States  
 Baldino, Jr., Frank, Landenberg, PA,  
 United States  
 PA Cephalon, Inc., West Chester, PA,  
 United States (U.S. corporation)  
 PI US 5093317 920303  
 AI US 89-361595 890605 (7)  
 DT Utility  
 LN.CNT 858  
 INCL INCLM: 514/012.000  
 INCLS: 514/003.000; 514/004.000;  
 514/885.000; 514/903.000;  
 514/021.000; 424/556.000;  
 424/570.000  
 NCL NCLM: 514/012.000  
 NCLS: 424/556.000; 424/570.000;  
 514/003.000; 514/004.000;  
 514/021.000; 514/885.000;  
 514/903.000  
 IC [5]  
 ICM: A61K037-36  
 ICS: A61K037-26  
 EXF 424/98; 424/556; 424/570; 514/3;  
 514/4; 514/12; 514/21; 514/885;  
 514/903  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 71 OF 73 USPATFULL  
 AN 91:84437 USPATFULL  
 TI Method for preventing tissue damage  
 after an ischemic episode  
 IN Sheffield, Warren D., Lebanon, NJ,  
 United States  
 PA Ethicon, Inc., Somerville, NJ, United  
 States (U.S. corporation)  
 PI US 5057494 911015  
 AI US 88-227579 880803 (7)  
 DT Utility

LN.CNT 487  
 INCL INCLM: 514/012.000  
 INCLS: 514/021.000  
 NCL NCLM: 514/012.000  
 NCLS: 514/021.000  
 IC [5]  
 ICM: A61K037-02  
 ICS: A61K037-36  
 EXF 514/12; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
  
 L6 ANSWER 72 OF 73 USPATFULL  
 AN 88:441 USPATFULL  
 TI Apparatus and method for adjusting  
 heart/pacer rate relative to  
 cardiac pCO<sub>2</sub> to obtain a required  
 cardiac output  
 IN Koning, Gerrit, Vries, Netherlands  
 Schroepel, Edward A., Miamar, FL,  
 United States  
 PA Teletronics N.V., Curacao,  
 Netherlands Antilles (non-U.S.  
 corporation)  
 PI US 4716887 880105  
 AI US 85-722575 850411 (6)  
 DT Utility  
 LN.CNT 946  
 INCL INCLM: 128/419.000PG  
 INCLS: 128/635.000  
 NCL NCLM: 607/024.000  
 NCLS: 600/353.000; 607/016.000;  
 607/022.000  
 IC [4]  
 ICM: A61N001-36  
 EXF 128/635; 128/2; 128/419PG  
  
 L6 ANSWER 73 OF 73 USPATFULL  
 AN 87:82990 USPATFULL  
 TI Novel phosphotyrosyl protein  
 phosphatase  
 IN Liang, Theming, Miami, FL, United  
 States  
 Slater, Eve E., Short Hills, NJ,  
 United States  
 PA Merck & Co., Inc., Rahway, NJ, United  
 States (U.S. corporation)  
 PI US 4710469 871201  
 AI US 86-858622 860502 (6)  
 DT Utility  
 LN.CNT 638  
 INCL INCLM: 435/194.000  
 INCLS: 530/352.000  
 NCL NCLM: 435/194.000  
 NCLS: 530/352.000  
 IC [4]  
 ICM: C12N009-12  
 EXF 435/194; 530/352  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 71 kwic

L6 ANSWER 71 OF 73 USPATFULL  
 SUMM . . . macroscopic area of necrosis.  
 Tissues that are likely to  
 be affected by a reduction of blood  
 supply and oxygen are  
 central nervous system (CNS),  
 myocardial, renal, spleen, intestinal  
 and lung tissues.  
 SUMM . . . an area of the heart muscle  
 usually as a result of  
 occlusion of a coronary artery; and  
 cerebral ischemia or

**stroke**, which is a neurological affliction resulting from the sudden reduction in cerebral blood supply. The term "**stroke**" (sometimes called apoplexy) is a lay term which refers to the sudden diminution or loss of consciousness, sensation and voluntary motion caused by rupture or obstruction of an artery of the **brain**. **Stroke** is usually more specifically described by the nature of the underlying disturbance, e.g. thrombosis, hemorrhage or embolism.

SUMM Cerebral ischemia may be distinguished from hypoxia, which is the interference with the oxygen supply to the **brain** despite a relatively normal cerebral blood flow and normal perfusion pressure. Cerebral hypoxia occurs for a variety of reasons, including. . .

SUMM . . . event that is sufficiently severe and in an appropriate location to leave persistent disability but is short of a calamitous **stroke**, is defined as a partial nonprogressing **stroke** (PNS). The ultimate in severity of ischemia produces a more major degree of permanent neurologic disability, sometimes referred to as a completed **stroke**.

In those cases where the ischemia has been prolonged, neuronal cell death occurs. The **brain** softens and the margins between the gray and white matter become indistinct. Under the microscope the neurons (if still present). . .

SUMM Present therapies for treating or preventing ischemic events, such as cerebral **stroke**, include risk factor management, anti-spasmodic drugs, anti-thrombotic drugs and surgery. These therapies have disadvantages and are not always successful.

Therefore, . . . methods for the direct protection of neurons and/or glia cells (aka neuroglia cells, which are non-neuronal cellular elements of the **central** and **peripheral nervous systems**) following cerebral ischemia and the present invention provides such methods.

SUMM . . . FGF may be beneficial in the treatment of Alzheimer's disease as well as treatment of other neurodegenerative disorders of the **CNS** involving loss of non-cholinergic neurons such as **stroke**, epilepsy or ischemia. In spite of the known neurotrophic nature of FGF, prior to the present invention, no one has. . .

SUMM . . . therewith. The growth factor may be used alone or in combination with other growth factors, such as FGF, NGF, plateletderived **growth factor**, insulin-like **growth factor** or transforming growth factor (alpha or beta). The EGF may be administered to the patient separately or in combination with. . .

SUMM . . . generally in the range of 2-5 minutes. In one embodiment, the present methods may be used to treat neuronal or **CNS** tissue, such as is present in the **brain** and spinal cord of the **CNS**. It is envisioned that the present methods may also be useful for treating other types of tissues such as myocardial. . .

SUMM In those instances where **CNS** tissue is to be treated, direct injection into the **CNS** is preferred, such as by intracerebral or intraventricular injection or by injection into the cerebro- spinal fluid or spinal cord. For injection into the **CNS**, catheters, needles and syringes may be used. Infusion of the EGF or FGF via a catheter into the **brain** is an alternative method of administration.

SUMM . . . merely for illustrative Purposes. For instance, the present methods may be used to minimize damage and increase survival time in **stroke** patients. They may be used as a preventative treatment of TIA patients to reduce subsequent serious **stroke** and increase patient and cell survival.

They may be used to reduce risk for spinal ischemia and in cases of. . . time available during surgery when aortic clamping is used. The present invention may be used to treat indications affecting the **brain**, such as **stroke**, cardiac arrest and post-resuscitation damage to the **brain** (e.g., from drowning or subarachnoidal hemorrhage). Indications affecting the heart that may be treated are, for example: post myocardial infarct. . .

DETD The present example is based on a surgical procedure that has been developed to study the effects of cerebral or **brain** ischemia in the unanesthetized gerbil. The methodology is based upon the surgical isolation and instrumentation of both common carotid arteries. . . occlusion are readily demonstrated by the occurrence of altered spontaneous locomotor activity at various times postischemia. Behavioral changes consequent to

**stroke** are useful and pertinent as a means of evaluation in this model of nonlethal transient ischemia. Emotional lability, depression, agitation and motor and cognitive deficits are common after **stroke**. The psychomotor depression noted immediately after transient ischemia in this gerbil model mimics the clinical situation in humans. Spontaneous motor. . . DEDT . . . ligatures. Spontaneous motor activity was then periodically monitored over seven days followed by animal sacrifice and blinded histological evaluation of brain sections. EGF (0.1 and 1.0 mg/kg) and FGF (0.1, 1.0 and 10.0 mg/kg) were given intraperitoneally in saline at one. . .

=> d ab

L6 ANSWER 1 OF 73 USPATFULL  
AB Disclosed are nucleic acids encoding novel neurotrophic factors, designated NNT-1. Also disclosed are amino acid sequences for NNT-1 polypeptides, methods for preparing NNT-1 polypeptides, and other related aspects.

=> d 50-59

L6 ANSWER 50 OF 73 USPATFULL  
AN 97:1574 USPATFULL  
TI Fused pyrrolocarbazoles  
IN Hudkins, Robert L., Chester Springs, PA, United States  
Knight, Jr., Ernest, Wilmington, DE, United States  
PA Cephalon, Inc., West Chester, PA, United States (U.S. corporation)  
PI US 5591855 970107  
AI US 95-427160 950424 (8)  
RLI Continuation-in-part of Ser. No. US 94-323755, filed on 14 Oct' 1994, now patented, Pat. No. US 5475110  
DT Utility  
LN.CNT 3293  
INCL INCLM: 546/256.000  
INCLS: 546/022.000; 546/276.700;  
548/417.000; 548/110.000;  
548/103.000  
NCL NCLM: 546/256.000  
NCLS: 546/276.700; 548/103.000;  
548/110.000; 548/417.000  
IC [6]  
ICM: C07D487-06  
EXF 548/417; 546/256; 546/271  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 73 USPATFULL  
AN 96:120775 USPATFULL  
TI DNA encoding tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders

IN Roy, Soumitra, San Francisco, CA, United States  
Vehar, Gordon A., San Carlos, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5589363 961231  
AI US 94-246978 940520 (8)  
RLI Division of Ser. No. US 91-714819, filed on 13 Jun 1991, now patented, Pat. No. US 5346991  
DT Utility  
LN.CNT 2528  
INCL INCLM: 435/069.600  
INCLS: 530/381.000; 536/023.500;  
536/023.400; 435/172.300;  
435/240.200; 435/252.300  
NCL NCLM: 435/069.600  
NCLS: 435/172.300; 435/252.300;  
435/325.000; 435/348.000;  
435/358.000; 435/369.000;  
435/419.000; 530/381.000;  
536/023.400; 536/023.500  
IC [6]  
ICM: C07K014-745  
ICS: C12N001-13; C12N015-12; C12N015-63  
EXF 435/69.6; 435/172.3; 435/252.3;  
435/240.1; 435/320.1; 435/240.2;  
530/350; 530/381; 536/23.5; 536/23.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L6 ANSWER 52 OF 73 USPATFULL  
AN 96:111367 USPATFULL  
TI Generation of neural precursor cell lines  
IN Bernard, Ora, North Balwyn, Australia  
Bartlett, Perry F., North Carlton, Australia  
PA Amrad Corporation Limited, Australia (non-U.S. corporation)  
PI US 5580777 961203  
AI US 94-330114 941027 (8)  
RLI Continuation of Ser. No. US 92-935357, filed on 27 Aug 1992, now abandoned which is a continuation of Ser. No. US 90-536423, filed on 28 Jun 1990, now abandoned  
PRAI AU 87-5131 871029  
DT Utility  
LN.CNT 924  
INCL INCLM: 435/240.200  
INCLS: 435/172.300; 435/320.100  
NCL NCLM: 435/172.300  
NCLS: 435/320.100; 435/325.000;  
435/354.000; 435/368.000;  
435/373.000; 435/377.000  
IC [6]  
ICM: C12N015-00  
ICS: C12N005-00  
EXF 435/172.3; 435/320.1; 435/240.2  
L6 ANSWER 53 OF 73 USPATFULL  
AN 96:111313 USPATFULL  
TI Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease  
IN Foulkes, J. Gordon, Huntington Station, NY, United States  
Liechtfried, Franz E., Vienna, Austria  
Pieler, Christian, Vienna, Austria  
Stephenson, John R., Santa Cruz, CA, United States

Case, Casey C., Lynbrook, NY, United States  
PA Oncogene Science, Inc., Uniondale, NY, United States (U.S. corporation)  
PI US 5580722 961203  
AI US 92-832905 920207 (7)  
RLI Continuation-in-part of Ser. No. US 90-555196, filed on 18 Jul 1990, now abandoned which is a continuation-in-part of Ser. No. US 89-382712, filed on 18 Jul 1989, now abandoned  
DT Utility  
LN.CNT 4011  
INCL INCLM: 435/006.000  
INCLS: 435/091.100; 435/091.200; 935/077.000; 935/078.000  
NCL NCLM: 435/006.000  
NCLS: 435/091.100; 435/091.200; 935/077.000; 935/078.000  
IC [6]  
ICM: C12P019-34  
ICS: C12Q001-68  
EXF 435/6; 435/91; 435/91.1; 435/91.2; 935/77; 935/78  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 73 USPATFULL  
AN 96:101657 USPATFULL  
TI Cardiac hypertrophy factor  
IN Baker, Joffre, El Granada, CA, United States  
Chien, Kenneth, La Jolla, CA, United States  
King, Kathleen, Pacifica, CA, United States  
Pennica, Diane, Burlingame, CA, United States  
Wood, William, San Mateo, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)  
PI US 5571893 961105  
AI US 94-286304 940805 (8)  
RLI Continuation of Ser. No. US 94-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615  
DT Utility  
LN.CNT 4056  
INCL INCLM: 530/350.000  
INCLS: 530/399.000; 530/351.000; 930/140.000  
NCL NCLM: 530/350.000  
NCLS: 530/351.000; 530/399.000; 930/140.000  
IC [6]  
ICM: C07K014-52  
ICS: A61K038-19  
EXF 530/350; 530/399; 530/351; 514/12; 930/140  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 55 OF 73 USPATFULL  
AN 96:101443 USPATFULL  
TI Detection and amplification of candoitrophin-1(cardiac hypertrophy factor)  
IN Baker, Joffre, El Granada, CA, United States

Chien, Kenneth, La Jolla, CA, United States  
King, Kathleen, Pacifica, CA, United States  
Pennica, Diane, Burlingame, CA, United States  
Wood, William, San Mateo, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)  
PI US 5571675 961105  
AI US 95-444083 950517 (8)  
RLI Division of Ser. No. US 94-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 94-233609, filed on 25 Apr 1994  
DT Utility  
LN.CNT 4298  
INCL INCLM: 435/006.000  
INCLS: 435/091.200; 435/091.210; 536/024.300; 536/024.310; 536/024.320; 536/024.330  
NCL NCLM: 435/006.000  
NCLS: 435/091.200; 435/091.210; 536/024.300; 536/024.310; 536/024.320; 536/024.330  
IC [6]  
ICM: C12Q001-68  
ICS: C12P019-34; C07H021-04  
EXF 435/6; 435/91.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 73 USPATFULL  
AN 96:94687 USPATFULL  
TI Thio-retinaco ozonide and enhanced biological activity of thio-retinaco ozonide in combination with interferon  
IN McCullly, Kilmer S., 15 Wildwood St., Winchester, MA, United States 01890  
PI US 5565558 961015  
AI US 94-366638 941230 (8)  
DT Utility  
LN.CNT 778  
INCL INCLM: 536/026.400  
INCLS: 536/026.410; 549/003.000; 549/029.000; 549/060.000; 556/138.000  
NCL NCLM: 536/026.400  
NCLS: 536/026.410; 549/003.000; 549/029.000; 549/060.000; 556/138.000  
IC [6]  
ICM: C07H019-167  
ICS: A61K031-365; C07D411-00; C07D333-20  
EXF 530/351; 424/85.4; 424/85.5; 424/85.6; 424/85.7; 536/26.4; 536/26.41; 549/3; 549/29; 549/60; 556/138  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 57 OF 73 USPATFULL  
AN 96:82674 USPATFULL  
TI Methods for neuroprotection  
IN Simpkins, James W., Gainesville, FL, United States  
Singh, Meharvan, Gainesville, FL, United States

Bishop, Jean, Jacksonville, FL, United States  
 PA University of Florida, Gainesville, FL, United States (U.S. corporation)  
 PI US 5554601 960910  
 AI US 94-318042 941004 (8)  
 RLI Continuation-in-part of Ser. No. US 93-149175, filed on 5 Nov 1993, now abandoned  
 DT Utility  
 LN.CNT 1532  
 INCL INCLM: 514/182.000  
 INCLS: 514/181.000  
 NCL NCLM: 514/182.000  
 NCLS: 514/181.000  
 IC [6]  
 ICM: A61K031-56  
 EXF 514/171; 514/170; 514/169; 514/179; 514/181; 514/182  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 73 USPATFULL  
 AN 96:60798 USPATFULL  
 TI Cardiac hypertrophy factor and uses therefor  
 IN Baker, Joffre, El Granada, CA, United States  
 Chien, Kenneth, La Jolla, CA, United States  
 King, Kathleen, Pacifica, CA, United States  
 Pennice, Diane, Burlingame, CA, United States  
 Wood, William, San Mateo, CA, United States  
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
 The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
 PI US 5534615 960709  
 AI US 94-233609 940425 (8)  
 DT Utility  
 LN.CNT 3897  
 INCL INCLM: 530/350.000  
 INCLS: 530/380.000; 424/569.000; 424/570.000  
 NCL NCLM: 530/350.000  
 NCLS: 424/569.000; 424/570.000; 530/380.000  
 IC [6]  
 ICM: C07K001-00  
 ICS: A61K035-14; A61K035-30  
 EXF 530/350; 530/380; 424/569; 424/570  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 59 OF 73 USPATFULL  
 AN 96:53046 USPATFULL  
 TI Transferrin receptor specific antibody-neuropharmaceutical agent conjugates  
 IN Friden, Phillip M., Bedford, MA, United States  
 PA Alkermes, Inc., Cambridge, MA, United States (U.S. corporation)  
 PI US 5527527 960618  
 AI US 93-4986 930115 (8)  
 RLI Continuation-in-part of Ser. No. US 92-846830, filed on 6 Mar 1992, now patented, Pat. No. US 5182107 which is a continuation-in-part of Ser. No. US 89-404089, filed on 7 Sep

1989, now patented, Pat. No. US 5154924  
 DT Utility  
 LN.CNT 1464  
 INCL INCLM: 424/178.100  
 INCLS: 530/391.100; 530/391.700; 530/399.000  
 NCL NCLM: 424/178.100  
 NCLS: 530/391.100; 530/391.700; 530/399.000  
 IC [6]  
 ICM: A61K039-44  
 ICS: C07K014-48; C07K016-46; C07K017-02  
 EXF 530/391.1; 530/391.7; 530/399; 530/394; 530/359; 530/303; 530/315; 530/388; 530/389; 514/3; 514/8; 514/12; 514/21; 514/7; 424/85.91; 424/178.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 40-49

L6 ANSWER 40 OF 73 USPATFULL  
 AN 97:51729 USPATFULL  
 TI Methods for the preparation of nucleic acids for in vivo delivery  
 IN Grinstaff, Mark W., Pasadena, CA, United States  
 Soon-Shiong, Patrick, Los Angeles, CA, United States  
 Wong, Michael, Champaign, IL, United States  
 Sandford, Paul A., Los Angeles, CA, United States  
 Suslick, Kenneth S., Champaign, IL, United States  
 Desai, Neil P., Los Angeles, CA, United States  
 PA Vivorx Pharmaceuticals, Inc., Santa Monica, CA, United States (U.S. corporation)  
 PI US 5639473 970617  
 AI US 95-483295 950607 (8)  
 RLI Division of Ser. No. US 94-200235, filed on 22 Feb 1994, now patented, Pat. No. US 5498421 which is a continuation-in-part of Ser. No. US 93-23698, filed on 22 Feb 1993, now patented, Pat. No. US 5439686 And a continuation-in-part of Ser. No. US 93-35150, filed on 26 Mar 1993, now patented, Pat. No. US 5362478  
 DT Utility  
 LN.CNT 3232  
 INCL INCLM: 424/450.000  
 INCLS: 424/482.000; 424/488.000; 424/486.000; 424/009.510  
 NCL NCLM: 424/450.000  
 NCLS: 424/009.510; 424/482.000; 424/486.000; 424/488.000  
 IC [6]  
 ICM: A61K009-127  
 EXF 424/450; 424/482; 424/488; 424/486; 424/9.51  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 73 USPATFULL  
 AN 97:47123 USPATFULL  
 TI Methods for the preparation of blood substitutes for in vivo delivery

IN Grinstaff, Mark W., Pasadena, CA,  
United States  
Soon-Shiong, Patrick, Los Angeles, CA,  
United States  
Wong, Michael, Champaign, IL, United  
States  
Sandford, Paul A., Los Angeles, CA,  
United States  
Suslick, Kenneth S., Champaign, IL,  
United States  
Desai, Neil P., Los Angeles, CA,  
United States  
PA Vivox Pharmaceuticals, Inc., Santa  
Monica, CA, United States  
(U.S. corporation)  
PI US 5635207 970603  
AI US 95-480621 950607 (8)  
RLI Division of Ser. No. US 94-200235,  
filed on 22 Feb 1994, now  
patented, Pat. No. US 5498421 which is  
a continuation-in-part of  
Ser. No. US 93-23698, filed on 22 Feb  
1993, now patented, Pat. No.  
US 5439686 And a continuation-in-part  
of Ser. No. US 93-35150,  
filed on 26 Mar 1993, now patented,  
Pat. No. US 5362478  
DT Utility  
LN.CNT 3309  
INCL INCLM: 424/450.000  
INCLS: 424/489.000; 424/001.170  
NCL NCLM: 424/450.000  
NCLS: 424/001.170; 424/489.000  
IC [6]  
ICM: A61K009-127  
EXF 424/1.17; 424/450; 424/489  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 73 USPATFULL  
AN 97:42862 USPATFULL  
TI Method for producing in vivo delivery  
of therapeutic agents via  
liposomes  
IN Dzau, Victor J., 12101 Dawn La., Los  
Altos Hills, CA, United  
States 94022  
Kaneda, Yasufumi, Molecular & Cellular  
Institute, Osaka  
University, 1-3, Yamada-oka, Suita-  
City, Osaka 565, Japan  
PI US 5631237 970520  
AI US 94-241372 940510 (8)  
RLI Continuation-in-part of Ser. No. US  
92-995022, filed on 22 Dec  
1992, now abandoned  
DT Utility  
LN.CNT 2435  
INCL INCLM: 514/044.000  
INCLS: 424/450.000; 424/417.000;  
428/402.200; 264/004.100;  
264/004.300; 264/004.600  
NCL NCLM: 514/044.000  
NCLS: 264/004.100; 264/004.300;  
264/004.600; 424/417.000;  
424/450.000; 428/402.200  
IC [6]  
ICM: A61K048-00  
ICS: A61K009-127  
EXF 514/44; 514/2; 424/93.1; 424/450;  
424/283.1; 424/1.21; 424/1.25;  
435/320.1; 435/69.1; 435/5; 435/193  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 73 USPATFULL  
AN 97:38416 USPATFULL

TI Hybridomas producing antibodies to  
cardiac hypertrophy factor  
IN Baker, Joffre, El Granada, CA, United  
States  
Chien, Kenneth, La Jolla, CA, United  
States  
King, Kathleen, Pacifica, CA, United  
States  
Pennica, Diane, Burlingame, CA, United  
States  
Wood, William, San Mateo, CA, United  
States  
PA Genentech, Inc., United States (U.S.  
corporation)  
The Regents of the University of  
California, United States (U.S.  
corporation)  
PI US 5627073 970506  
AI US 95-443129 950517 (8)  
RLI Division of Ser. No. US 94-286304,  
filed on 5 Aug 1994 which is a  
continuation-in-part of Ser. No. US  
94-233609, filed on 25 Apr  
1994, now abandoned  
DT Utility  
LN.CNT 4258  
INCL INCLM: 435/331.000  
INCLS: 435/070.210; 435/172.100;  
435/069.600; 435/252.330;  
435/332.000; 435/336.000;  
530/387.900; 530/388.230;  
530/387.300; 530/391.300;  
424/139.100; 424/145.100  
NCL NCLM: 435/331.000  
NCLS: 424/139.100; 424/145.100;  
435/069.600; 435/070.210;  
435/172.100; 435/252.330;  
435/332.000; 435/336.000;  
530/387.300; 530/387.900;  
530/388.230; 530/391.300  
IC [6]  
ICM: C12N005-18  
ICS: C12N005-22  
EXF 424/139.1; 424/145.1; 424/152.1;  
424/158.1; 424/172.1; 424/178.1;  
424/136.1; 435/69.6; 435/70.21;  
435/172.2; 435/172.1; 435/172.3;  
435/240.27; 435/252.33; 530/387.3;  
530/387.9; 530/388.15;  
530/388.23; 530/388.24; 530/391.3;  
530/389.2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 73 USPATFULL  
AN 97:36158 USPATFULL  
TI Method for administering neurologic  
agents to the **brain**  
IN Frey, II, William H., North Oaks, MN,  
United States  
PA Ramsey Foundation, St. Paul, MN,  
United States (U.S. corporation)  
PI US 5624898 970429  
AI US 94-361877 941222 (8)  
RLI Continuation of Ser. No. US 93-161337,  
filed on 2 Dec 1993, now  
abandoned which is a continuation of  
Ser. No. US 92-879556, filed  
on 4 May 1992, now abandoned which is  
a continuation of Ser. No.  
US 89-446308, filed on 5 Dec 1989, now  
abandoned  
DT Utility  
LN.CNT 620  
INCL INCLM: 514/012.000

INCLS: 530/300.000; 530/324.000;  
530/402.000; 424/400.000  
NCL NCLM: 514/012.000  
NCLS: 424/400.000; 530/300.000;  
530/324.000; 530/402.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K038-02; C07K005-00; C07K001-  
00  
EXF 514/12; 530/324; 530/402; 530/810;  
530/300; 424/400; 424/450  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 73 USPATFULL  
AN 97:36067 USPATFULL  
TI Antibodies to cardiac hypertrophy  
factor and uses thereof  
IN Baker, Joffre, El Granada, CA, United  
States  
Chien, Kenneth, La Jolla, CA, United  
States  
King, Kathleen, Pacifica, CA, United  
States  
Pennica, Diane, Burlingame, CA, United  
States  
Wood, William, San Mateo, CA, United  
States  
PA Genentech, Inc., South San Francisco,  
CA, United States (U.S.  
corporation)  
The Regents of the University of  
California, Oakland, CA, United  
States (U.S. corporation)  
PI US 5624806 970429  
AI US 95-442745 950517 (8)  
RLI Division of Ser. No. US 94-286304,  
filed on 5 Aug 1994 which is a  
continuation of Ser. No. US 94-233609,  
filed on 25 Apr 1994, now  
patented, Pat. No. US 5534615  
DT Utility  
LN.CNT 4254  
INCL INCLM: 435/007.100  
INCLS: 435/240.270; 530/387.900;  
530/388.850; 530/387.300;  
530/391.300  
NCL NCLM: 435/007.100  
NCLS: 435/331.000; 435/344.100;  
530/387.300; 530/387.900;  
530/388.850; 530/391.300  
IC [6]  
ICM: G01N033-53  
ICS: C12N005-12; C07K016-22  
EXF 530/387.1; 530/389.1; 530/389.2;  
530/388.24; 530/387.24;  
530/387.9; 530/388.85; 530/391.3;  
530/888.1; 530/388.15;  
530/387.3; 424/130.1; 424/145.1;  
424/139.1; 424/7.24; 424/156.1;  
424/141.1; 424/142.1; 424/133.1;  
424/178.1; 424/136.1; 435/240.27;  
435/70.21; 435/7.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 73 USPATFULL  
AN 97:20504 USPATFULL  
TI Treatment of congestive heart failure  
IN Clark, Ross G., Pacifica, CA, United  
States  
Jin, Hongkui, San Bruno, CA, United  
States  
Paoni, Nicholas F., Belmont, CA,  
United States  
Yang, Renhui, San Bruno, CA, United  
States

PA Genentech, Inc., South San Francisco,  
CA, United States (U.S.  
corporation)  
PI US 5610134 970311  
AI US 94-333909 941103 (8)  
RLI Continuation of Ser. No. US 94-284859,  
filed on 2 Aug 1994 which  
is a continuation of Ser. No. US 94-  
227923, filed on 15 Apr 1994,  
now abandoned  
DT Utility  
LN.CNT 1257  
INCL INCLM: 514/002.000  
INCLS: 514/423.000  
NCL NCLM: 514/002.000  
NCLS: 514/423.000  
IC [6]  
ICM: A61K038-00  
ICS: A61K031-40  
EXF 514/2; 514/423  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 73 USPATFULL  
AN 97:14767 USPATFULL  
TI Recombinant human basic fibroblast  
growth factor  
IN Fiddes, John C., Palo Alto, CA, United  
States  
Abraham, Judith A., Sunnyvale, CA,  
United States  
PA Scios Inc., Mountain View, CA, United  
States (U.S. corporation)  
PI US 5604293 970218  
AI US 94-221462 940401 (8)  
RLI Continuation of Ser. No. US 92-860688,  
filed on 30 Mar 1992, now  
abandoned which is a continuation of  
Ser. No. US 87-50706, filed  
on 15 May 1987, now abandoned which is  
a continuation-in-part of  
Ser. No. US 86-869382, filed on 30 May  
1986, now abandoned And  
Ser. No. US 85-809163, filed on 16 Dec  
1985, now patented, Pat.  
No. US 5439818 And Ser. No. US 85-  
775521, filed on 12 Sep 1985,  
now abandoned  
DT Utility  
LN.CNT 1715  
INCL INCLM: 530/399.000  
INCLS: 930/010.000  
NCL NCLM: 530/399.000  
NCLS: 930/010.000  
IC [6]  
ICM: C07K014-50  
EXF 530/399; 530/350; 514/12; 930/10  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 73 USPATFULL  
AN 97:5885 USPATFULL  
TI Family of map2 protein kinases  
IN Boulton, Teri G., Irving, TX, United  
States  
Cobb, Melanie H., Dallas, TX, United  
States  
Yancopoulos, George D., Elmhurst, NY,  
United States  
Nye, Steven, New York, NY, United  
States  
Panayotatos, Nikos, Orangeburg, NY,  
United States  
PA Board of Regents, Univ. of Texas,  
Dallas, TX, United States (U.S.  
corporation)

Regeneron Pharmaceuticals, Inc.,  
Tarrytown, NY, United States  
(U.S. corporation)  
PI US 5595904 970121  
AI US 94-176620 940103 (8)  
RLI Division of Ser. No. US 91-701544,  
filed on 16 May 1991, now  
abandoned Continuation-in-part of Ser.  
No. US 90-532004, filed on  
1 Jun 1990, now abandoned  
DT Utility  
LN.CNT 2571  
INCL INCLM: 435/240.200  
INCLS: 435/243.000; 435/252.800;  
435/254.200; 435/320.100;  
536/023.500  
NCL NCLM: 435/325.000  
NCLS: 435/243.000; 435/252.800;  
435/254.200; 435/320.100;  
435/348.000; 435/353.000;  
536/023.500  
IC [6]  
ICM: C12N005-00  
EXF 800/2; 800/205; 800/DIG.1; 435/254.2;  
435/172.3; 435/240.1;  
435/240.2; 435/320.1; 435/243;  
435/252.8; 536/23.1; 536/23.5;  
536/24.31  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 73 USPATFULL  
AN 97:3856 USPATFULL  
TI Fused pyrrolocarbazoles  
IN Hudkins, Robert L., Chester Springs,  
PA, United States  
Knight, Jr., Ernest, Wilmington, DE,  
United States  
PA Cephalon, Inc., West Chester, PA,  
United States (U.S. corporation)  
PI US 5594009 970114  
AI US 95-452335 950526 (8)  
RLI Continuation-in-part of Ser. No. US  
95-427160, filed on 24 Apr  
1995 which is a continuation-in-part  
of Ser. No. US 94-323755,  
filed on 14 Oct 1994, now patented,  
Pat. No. US 5475110  
DT Utility  
LN.CNT 3770  
INCL INCLM: 514/338.000  
INCLS: 514/131.000; 514/140.000  
NCL NCLM: 514/338.000  
NCLS: 514/339.000; 514/410.000  
IC [6]  
ICM: A61K031-40  
EXF 514/410; 514/338; 514/339  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 44 kwic

L6 ANSWER 44 OF 73 USPATFULL  
TI Method for administering neurologic  
agents to the **brain**  
AB Disclosed is a method for transporting  
neurologic therapeutic  
agents to the **brain** by means of the  
olfactory neural  
pathway and a pharmaceutical  
composition useful in the treatment  
of **brain** disorders.  
SUMM The present invention is directed to a  
method for delivering

neurologic agents to the **brain** by  
means of the olfactory  
neural pathway and a pharmaceutical  
composition useful in the  
treatment of **brain** disorders.  
SUMM Alzheimer's disease is an age-  
associated neurodegenerative  
disorder of the **brain**. The disorder is  
characterized  
histopathologically by the formation  
and accumulation of  
neurofibrillary tangles and neuritic  
plaques in the **brain**  
. In particular, pathological changes  
associated with the disease  
extensively affect neurons in the  
olfactory bulb and its connected  
**brain** structures. Degeneration with loss  
of neurons has  
been observed in the hippocampal  
formation, amygdaloid nuclei,  
nucleus basalis of Meynert, locus  
ceruleus, and the  
**brainstem** raphe nuclei, all of which  
project to the  
olfactory bulb. These degenerative  
changes result in the loss of  
memory and. . .  
SUMM At present, there is no treatment for  
Alzheimer's disease which  
effectively prevents or retards the  
progressive neurodegeneration  
of the **brain** and the loss of smell and  
cognitive decline  
associated with the illness.  
Neurotrophic and neuritogenic  
factors, such as nerve growth. . .  
SUMM Neurotrophic and neuritogenic factors  
are agents that affect the  
survival and differentiation of  
neurons in the peripheral and  
**central nervous systems**. These growth  
promoting  
factors are signaling substances that  
are synthesized in tissues  
in response to neurons capable of  
responding. . . receptors on  
axon terminals, and can be  
internalized and retrogradely  
transported to the cell body of  
neurons. See M. Seiler,  
*Brain Res.* 300:33-39 (1984). Other  
naturally-occurring  
nerve growth promoting factors include  
gangliosides,  
phosphatidylserine (PS), **brain**-derived  
neurotrophic  
factor, fibroblast **growth factor**,  
**insulin**, **insulin-like growth**  
**factors**, ciliary neurotrophic factor and  
glia-derived  
nixin.  
SUMM Testing the effectiveness of  
potentially therapeutic agents  
against **brain** disease in animal  
toxicity studies and  
human trials has been hindered,  
however, by the inability of  
existing procedures to readily deliver  
adequate levels of the  
agent to affected areas of the **brain**  
over an extended  
period of time.

SUMM Some experimental therapeutic agents used in the treatment of Alzheimer's disease, such as GM-1 ganglioside, can be administered to the **brain** through the bloodstream because of their ability to traverse the blood-**brain** barrier. However, it is not clear that effective levels of the ganglioside reach the affected areas of the **brain**. SUMM Other potentially therapeutic agents, such as nerve growth factor (NGF), are unable to cross the blood-**brain** barrier and must be administered to the **brain** by other means. One such method of delivery is by an intracerebroventricular pump. Use of such a pump, however, necessitates . . . complications. Furthermore, administration of medication by pump does not facilitate selective delivery of medication solely to those areas of the **brain** affected by disease. Consequently, healthy areas of the **brain** may be adversely affected by the neurologic agent while some diseased areas may not receive a high enough level for. . . . SUMM An effective method of therapeutic intervention is needed to prevent and effectively treat **brain** diseases such as Alzheimer's disease, Parkinson's disease, nerve damage from cerebrovascular disorders such as **stroke**, and ordinary aging. Testing the potential of various neurologic agents is an important aspect of developing treatments for neurodegenerative diseases. Since existing methods of testing possible therapeutic agents and treating **brain** disorders are of limited benefit, a goal of the present invention is to develop a procedure to effectively deliver neurologic agents to the **brain**. A particular goal of the invention is to develop a method of delivering neurologic substances to the **brain** to augment the level of activity against **brain** diseases by naturally-occurring substances. A further goal is to develop a means of selective delivery of a neurologic agent only to areas of the **brain** which are damaged by a **brain** disorder. Still another objective is to develop a composition that can cause absorption of the neurologic agent into olfactory neurons and along the olfactory neural pathway to damaged neurons in the **brain**. Another goal is to provide prophylactic treatment of neurodegenerative diseases and to treat and/or prevent associated loss of smell.

SUMM . . . other goals are met by the present invention which is directed to a method to convey therapeutic substances to the **brain** for the treatment of neurologic or psychiatric disorders and a pharmaceutical composition capable of delivering a neurologic agent to the **brain** for use in such a method of treatment. More specifically, the method of medical treatment involves intranasal administration of a neurologic agent which may be absorbed into the olfactory system of the **brain** for the treatment of **brain** disorders such as Alzheimer's disease, Parkinson's disease, affective disorders such as depression and mania, nerve damage from cerebrovascular disorders such as **stroke**, and the like. SUMM . . . neurologic substance is administered to the nasal cavity of a patient affected with Alzheimer's disease or other disease afflicting the **brain**. The neurologic factor may be applied alone or in combination with other substances. Particular formulations may include the neurologic substance. . . of the neurologic agent through the nasal mucosa and/or along the olfactory neural pathway to damaged nerve cells of the **brain**. SUMM . . . the invention may employ transneuronal anterograde and retrograde transport of the neurologic agent entering through the olfactory system of the **brain**. Once the agent is dispensed into the nasal cavity, the agent may transport through the nasal mucosa by means of the peripheral olfactory neurons into the olfactory bulb and interconnected areas of the **brain** such as the hippocampal formation, amygdaloid nuclei, nucleus basalis of Meynert, locus ceruleus, and the **brainstem** raphe nuclei. The agent alone may facilitate this movement into the **brain**. Alternatively, the carrier and/or other transfer-promoting factors may assist in the transport of the neurologic agent into and along the. . . . SUMM . . . of nerve growth promoting factors to peripheral nerve cells of the olfactory system, a purported entryway for causative agents of **brain** diseases, helps protect against disease in these nerve cells and regenerate injured nerve cells thereby forestalling the subsequent spread of disease to susceptible areas of the **brain**.

SUMM . . . to naturally occurring nerve growth promoting substances.

Among the preferred neurologic agents are gangliosides, phosphatylserine (PS), nerve growth factor (NGF), **brain**-derived neurotrophic factor, fibroblast growth factor, insulin, insulin-like growth factors, ciliary neurotrophic factor, glia-derived nexin, and cholinergic enhancing factors such as phosphoethanolamine and thyroid hormone T.3. GM-1 ganglioside and nerve. . . .

DETD . . . neurologic agent to the nasal cavity of a human or other mammal for the testing of potential therapeutic agents against **brain** disease and for the treatment of **brain** disorders such as Alzheimer's disease, Parkinson's disease, affective disorders such as depression and mania, nerve damage from cerebrovascular disorders such as **stroke**, or ordinary aging. In particular, the method delivers a neurologic agent to diseased areas of the **brain** by means of the olfactory neural pathway. The method may employ a pharmaceutical composition capable of transporting the neurologic agent to diseased neurons of the **brain**.

DETD The method of the invention may achieve delivery of neurologic substances to afflicted areas of the **brain** through transneuronal retrograde and anterograde transport mechanisms.

Delivery of neurologic agents to the **brain** by that transport system may be achieved in several ways. One technique comprises delivering the neurologic agent alone to the . . . nasal cavity. In this instance, the chemical characteristics of the agent itself facilitate its transport to diseased neurons in the **brain**. Alternatively, the agent may be combined with other substances that assist in transporting the agent to sites of damaged neurons. . . . substances are capable of delivering the agent to peripheral sensory neurons and/or along neural pathways to dysfunctioning areas of the **brain**. It is further preferred that the peripheral nerve cells of the olfactory neural pathway be utilized in order to deliver the neurologic agent to damaged neurons in those regions of the **brain** that are connected to the olfactory bulb.

DETD . . . be applied in non-toxic levels in order to provide an effective level of activity within the neural system against the

**brain** disease. It is further preferred that the neurologic agent promote nerve cell growth and survival or augment the activity of. . . other adjuvants to form a pharmaceutical composition. Among the preferred neurologic agents are gangliosides, nerve growth factor (NGF), phosphatidylserine (PS), **brain**-derived neurotrophic factor, fibroblast growth factor, insulin, insulin-like growth factors, ciliary neurotrophic factor, glia-derived nexin, and cholinergic enhancing factors such as phosphoethanolamine and thyroid hormone T.3. Among those agents that. . .

DETD . . . olfactory neurons rather than the capillaries within the respiratory epithelium. The invention prefers the transport of neurologic agents to the **brain** by means of the nervous system instead of the circulatory system so that potentially therapeutic agents that are unable to cross the blood-**brain** barrier from the bloodstream into the **brain** may be delivered to damaged neurons in the **brain**.

DETD . . . the absorption of the agent into the peripheral olfactory receptor cells. These peripheral neurons provide a direct connection between the **brain** and the outside environment due to their role in odor detection.

DETD The invention also provides a means for the prevention of **brain** disorders particularly in cases where the causative factor enters the **brain** through olfactory neurons. It is preferred that prophylactic treatments be employed where evidence indicates neuronal degeneration in the olfactory neurons as in the case of Alzheimer's disease and other related **brain** disorders. Prophylactic treatment of **brain** disease may involve the direct or indirect application of neurologic therapeutic agents to the olfactory epithelium. Such agents may be. . .

DETD . . . the absorption of the agent into the olfactory neurons. Potential neurologic agents include gangliosides, nerve growth factor (NGF), phosphatidylserine (PS), **brain**-derived neurotrophic factor, fibroblast growth factor, insulin, insulin-like growth factors, ciliary neurotrophic factor, glia-derived nexin, and cholinergic enhancing factors such as phosphoethanolamine and thyroid hormone T.3. GM-1 ganglioside and nerve growth factor

(NGF) are among those agents that are particularly preferred for prophylactic treatment of **brain** disorders.

DETD . . . further directed to a pharmaceutical composition comprising an amount of a neurologic agent which is effective in treating or preventing **brain** disorders in a mammal, when administered thereto, in combination with a pharmaceutically-acceptable vehicle such as a liquid or powdered carrier. . . .

DETD . . . such as synthesizing neurotransmitter substances. Among the neurologic agents that are preferred are nerve growth factor (NGF), gangliosides, phosphatidylserine (PS), **brain**-derived neurotrophic factor, fibroblast growth factor, insulin, insulin-like growth factors, ciliary neurotrophic factor, glia-derived nexin, and cholinergic enhancing factors such as phosphoethanolamine and thyroid hormone T.3.

DETD . . . pharmaceutical composition are lipophilic substances that may enhance absorption of the agent across the nasal membrane and delivery to the **brain** by means of the olfactory neural pathway. The neurologic agent may be mixed with a lipophilic adjuvant alone or in. . . .

DETD The present invention for a method of administering neurologic agents useful in the treatment of **brain** disorders such as Alzheimer's disease presents several advantages over currently available methods.

DETD . . . the present invention prefers the olfactory neural pathway rather than the bloodstream to deliver agents useful for the treatment of **brain** disorders such as Alzheimer's disease directly to the **brain**. Use of the olfactory system to transport a neurologic agent to the **brain** obviates the blood-**brain** barrier so that medications like nerve growth factor (NGF), a protein that cannot normally cross that barrier, can be delivered directly to the **brain**. Although the agent that is administered may be absorbed into the bloodstream as well as the olfactory neural pathway, the. . . . in fluids present in the bloodstream. As such, the invention provides an improved method of testing potential therapeutic agents against **brain** disease and of treating neurodegenerative disorders.

DETD . . . of the intranasal administration of the medication. The

olfactory system provides a direct connection between the outside environment and the **brain** thus providing quick and ready delivery of neurologic agents for treatment of neurologic disorders. Moreover, the means of applying a. . . .

DETD The application of a neurologic therapeutic agent to the nasal epithelium also helps prevent the spread of certain **brain** disorders by directly treating peripheral olfactory neurons that are injured by neurotoxins and other insults. Prophylactic treatment of these outlying nerve cells helps preclude the entrance of disease-causing agents into the **brain**. This method of treatment is particularly beneficial in cases of Alzheimer's disease where an environmental factor is suspected of being. . . .

DETD Another advantage of the invention is that it provides delivery of neurologic agents solely to those areas of the **brain** affected by disease while avoiding unwanted treatment of **brain** regions which are free of the disease. The method of the invention employs a neurologic agent or other substance that has an affinity for neuron receptor sites in order to facilitate delivery of the agent directly to the **brain** through the olfactory epithelium.

CLM What is claimed is:

1. A method for delivering a neurologic therapeutic agent to the **brain** of a mammal, comprising: applying an effective amount of the neurologic therapeutic agent directly to the olfactory epithelium of the. . . . an effective amount of lipophilic micelles, or a combination thereof; the neurologic agent being unable to be delivered to the **brain** from the circulatory system of the mammal by crossing the blood-**brain** barrier of the mammal; wherein the neurologic agent is absorbed through the olfactory epithelium of the nasal mucosa into olfactory neurons and an effective amount of the agent is transported into the **brain** of the mammal by means of the olfactory neural pathway to provide a protective effect on **brain** cells against **stroke**.
4. The method according to claim 1 wherein the agent is transported to the hippocampal formation, amygdaloid nuclei, nucleus basalis of Meynert, locus ceruleus, **brainstem** raphe nuclei, or any combination thereof.

5. The method according to claim 1 wherein the agent is transported to damaged neurons in the **brain**.

8. A method for delivering a neurologic therapeutic agent to the **brain** of a mammal, comprising: applying an effective amount of the neurologic therapeutic agent directly to the olfactory epithelium of the . . . an effective amount of lipophilic micelles, or a combination thereof; the neurologic agent being unable to be delivered to the **brain** from the circulatory system of the mammal by crossing the blood-**brain** barrier of the mammal; wherein the neurologic agent is absorbed through the olfactory epithelium of the nasal mucosa into olfactory neurons and an effective amount of the agent is transported into the **brain** of the mammal by means of the olfactory neural pathway to inhibit degeneration of nerve cells in the **brain**.

9. The method according to claim 8, wherein the **brain** cells are basal forebrain cholinergic neurons.

=> d 30-39

L6 ANSWER 30 OF 73 USPATFULL  
AN 97:73601 USPATFULL  
TI Compositions for inhibiting restenosis  
IN Weisz, Paul B., State College, PA,  
United States  
PA The Trustees of the University of  
Pennsylvania, Philadelphia, PA,  
United States (U.S. corporation)  
PI US 5658894 970819  
AI US 94-345011 941123 (8)  
RLI Continuation of Ser. No. US 92-900592,  
filed on 18 Jun 1992, now  
abandoned And a continuation-in-part  
of Ser. No. US 91-790320,  
filed on 12 Nov 1991, now abandoned  
which is a  
continuation-in-part of Ser. No. US  
91-691168, filed on 24 Apr  
1991, now abandoned which is a  
continuation of Ser. No. US  
89-397559, filed on 23 Aug 1989, now  
abandoned , said Ser. No. US  
-900592 which is a continuation-in-  
part of Ser. No. US 90-480407,  
filed on 15 Feb 1990, now patented,  
Pat. No. US 5183809, issued on  
2 Feb 1993  
DT Utility  
LN.CNT 1449  
INCL INCLM: 514/058.000  
INCLS: 514/021.000; 514/023.000;  
514/054.000; 514/060.000;

536/103.000; 530/810.000;  
530/812.000; 530/813.000  
NCL NCLM: 514/058.000  
NCLS: 514/021.000; 514/023.000;  
514/054.000; 514/060.000;  
530/810.000; 530/812.000;  
530/813.000; 536/103.000  
IC [6]  
ICM: A61K031-735  
ICS: C08B037-16  
EXF 514/21; 514/23; 514/54; 514/58;  
514/60; 536/103; 530/810; 530/812;  
530/813  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 73 USPATFULL  
AN 97:68499 USPATFULL  
TI Methods and compositions for  
stimulating neurite growth  
IN Armistead, David M., Maynard, MA,  
United States  
PA Vertex Pharmaceuticals Incorporated,  
Cambridge, MA, United States  
(U.S. corporation)  
PI US 5654332 970805  
AI US 95-486004 950608 (8)  
DT Utility  
LN.CNT 1225  
INCL INCLM: 514/533.000  
INCLS: 514/534.000; 514/330.000;  
514/423.000; 514/428.000;  
514/438.000; 514/538.000;  
514/547.000; 514/549.000;  
514/551.000; 514/465.000;  
514/466.000  
NCL NCLM: 514/533.000  
NCLS: 514/330.000; 514/423.000;  
514/428.000; 514/438.000;  
514/465.000; 514/466.000;  
514/534.000; 514/538.000;  
514/547.000; 514/549.000;  
514/551.000  
IC [6]  
ICM: A61K031-235  
ICS: A61K031-24; A61K031-40; A61K031-  
38; A61K031-44; A61K031-225;  
A61K031-22; A61K031-36  
EXF 514/533; 514/534; 514/330; 514/423;  
514/428; 514/438; 514/538;  
514/547; 514/549; 514/551; 514/465;  
514/466  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 73 USPATFULL  
AN 97:68346 USPATFULL  
TI Secreted proteins and polynucleotides  
encoding them  
IN Jacobs, Kenneth, Newton, MA, United  
States  
McCoy, John M., Reading, MA, United  
States  
LaVallie, Edward R., Tewksbury, MA,  
United States  
Racie, Lisa A., Acton, MA, United  
States  
Merberg, David, Acton, MA, United  
States  
Treacy, Maurice, Chestnut Hill, MA,  
United States  
Spaulding, Vikki, Billerica, MA,  
United States  
PA Genetics Institute, Inc., Cambridge,  
MA, United States (U.S.  
corporation)  
PI US 5654173 970805

AI US 96-702080 960823 (8)  
DT Utility  
LN.CNT 1685  
INCL INCLM: 435/069.100  
INCLS: 435/252.300; 435/326.000;  
536/023.500  
NCL NCLM: 435/069.100  
NCLS: 435/252.300; 435/326.000;  
536/023.500  
IC [6]  
ICM: C12P021-02  
ICS: C12N001-21; C12N005-10; C07H021-04  
EXF 435/69.1; 435/326; 435/252.3; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 73 USPATFULL  
AN 97:66223 USPATFULL  
TI OP-3-induced morphogenesis  
IN Oppermann, Hermann, Medway, MA, United  
States  
Ozkaynak, Engin, Milford, MA, United  
States  
Kuberampath, Thangavel, Medway, MA,  
United States  
Rueger, David C., Hopkinton, MA,  
United States  
Pang, Roy H. L., Etna, NH, United  
States  
Cohen, Charles M., Medway, MA, United  
States  
PA Creative BioMolecules, Inc.,  
Hopkinton, MA, United States (U.S.  
corporation)  
PI US 5652337 970729  
AI US 95-479666 950607 (8)  
RLI Division of Ser. No. US 92-971091,  
filed on 3 Nov 1992, now  
abandoned which is a continuation-in-  
part of Ser. No. US  
92-922813, filed on 31 Jul 1992, now  
abandoned which is a  
continuation-in-part of Ser. No. US  
91-752764, filed on 31 Aug  
1991, now abandoned which is a  
continuation-in-part of Ser. No. US  
91-667274, filed on 11 Mar 1991, now  
abandoned, said Ser. No. US  
92-971091, filed on 3 Nov 1992, now  
abandoned which is a  
continuation-in-part of Ser. No. US  
92-923780, filed on 31 Jul  
1992, now abandoned which is a  
continuation-in-part of Ser. No. US  
91-752764, filed on 30 Aug 1991, now  
abandoned And a  
continuation-in-part of Ser. No. US  
91-752857, filed on 30 Aug  
1991, now abandoned, each Ser. No. US  
- which is a  
continuation-in-part of Ser. No. US  
91-667274, filed on 11 Mar  
1991, now abandoned, said Ser. No. US  
92-971091, filed on 3 Nov  
1992, now abandoned which is a  
continuation-in-part of Ser. No. US  
92-938336, filed on 28 Aug 1992, now  
abandoned And a  
continuation-in-part of Ser. No. US  
92-938337, filed on 28 Aug  
1992, now abandoned, each Ser. No. US  
- which is a  
continuation-in-part of Ser. No. US  
91-753059, filed on 30 Aug

1991, now abandoned which is a  
continuation-in-part of Ser. No. US  
91-667274, filed on 11 Mar 1991, now  
abandoned, said Ser. No. US  
92-971091, filed on 3 Nov 1992, now  
abandoned which is a  
continuation-in-part of Ser. No. US  
92-938021, filed on 28 Aug  
1992, now abandoned which is a  
continuation-in-part of Ser. No. US  
91-752861, filed on 30 Aug 1991, now  
abandoned which is a  
continuation-in-part of Ser. No. US  
91-667274, filed on 11 Mar  
1991, now abandoned, said Ser. No. US  
92-971091, filed on 3 Nov  
1992, now abandoned which is a  
continuation-in-part of Ser. No. US  
92-945285, filed on 15 Sep 1992, now  
abandoned And a  
continuation-in-part of Ser. No. US  
92-945286, filed on 15 Sep  
1992, now abandoned, each Ser. No. US  
- which is a  
continuation-in-part of Ser. No. US  
91-752764, filed on 30 Aug  
1991, now abandoned, said Ser. No. US  
92-971091, filed on 3 Nov  
1992, now abandoned which is a  
continuation-in-part of Ser. No. US  
92-946235, filed on 16 Sep 1992, now  
abandoned And a  
continuation-in-part of Ser. No. US  
92-946238, filed on 16 Sep  
1992, now abandoned, each Ser. No. US  
- which is a  
continuation-in-part of Ser. No. US  
91-752764, filed on 30 Aug  
1991, now abandoned  
DT Utility  
LN.CNT 2887  
INCL INCLM: 530/350.000  
INCLS: 530/399.000  
NCL NCLM: 530/350.000  
NCLS: 530/399.000  
IC [6]  
ICM: C07K019-51  
EXF 530/350; 530/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 73 USPATFULL  
AN 97:66103 USPATFULL  
TI Treating disorders by application of  
**insulin-like**  
**growth factors** and analogs  
IN Lewis, Michael E., West Chester, PA,  
United States  
Kauer, James C., Kennett Square, PA,  
United States  
Smith, Kevin R., Parkesburg, PA,  
United States  
Callison, Kathleen V., Merchantville,  
NJ, United States  
Baldino, Frank, Landenberg, PA, United  
States  
Neff, Nicola, Wallingford, PA, United  
States  
Iqbal, Mohamed, Malvern, PA, United  
States  
PA Cephalon, Inc., West Chester, PA,  
United States (U.S. corporation)  
PI US 5652214 970729  
AI US 92-958903 921007 (7)

RLI Continuation-in-part of Ser. No. US 92-869913, filed on 15 Apr 1992, now abandoned which is a continuation-in-part of Ser. No. US 90-534139, filed on 5 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 89-361595, filed on 5 Jun 1989, now patented, Pat. No. US 5093317 DT Utility LN.CNT 2358 INCL INCLM: 514/012.000 INCLS: 514/021.000 NCL NCLM: 514/012.000 NCLS: 514/021.000 IC [6] ICM: A61K038-30 EXF 514/12; 514/9; 514/11; 514/2; 514/3; 514/21; 530/317; 530/324; 530/303  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 73 USPATFULL  
AN 97:66010 USPATFULL  
TI Nucleic acid encoding a novel morphogenic protein, OP-3  
IN Ozkaynak, Engin, Milford, MA, United States  
Oppermann, Hermann, Medway, MA, United States  
PA Creative BioMolecules, Inc., Hopkinton, MA, United States (U.S. corporation)  
PI US 5652118 970729  
AI US 95-480528 950607 (8)  
RLI Continuation of Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-922813, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-752764, filed on 31 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-923780, filed on 31 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-752764, filed on 30 Aug 1991, now abandoned And a continuation-in-part of Ser. No. US 91-752857, filed on 30 Aug 1991, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-938336, filed on 28 Aug 1992, now abandoned And a continuation-in-part of Ser. No. US 92-938337, filed on 28 Aug 1992, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-753059, filed on 30 Aug

1991, now abandoned which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-938021, filed on 28 Aug 1992, now abandoned which is a continuation-in-part of Ser. No. US 91-752861, filed on 30 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 91-667274, filed on 11 Mar 1991, now abandoned, said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-945285, filed on 15 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 92-945286, filed on 15 Sep 1992, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-752764, filed on 30 Aug 1991, now abandoned, said Ser. No. US 92-971091, filed on 3 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 92-946235, filed on 16 Sep 1992, now abandoned And a continuation-in-part of Ser. No. US 92-946238, filed on 16 Sep 1992, now abandoned, each Ser. No. US - which is a continuation-in-part of Ser. No. US 91-252764, filed on 30 Aug 1991, now abandoned DT Utility LN.CNT 3004 INCL INCLM: 435/069.100 INCLS: 435/252.300; 435/252.330; 435/070.100; 435/070.300; 435/071.100; 435/071.200; 435/320.100; 435/172.300; 435/325.000; 435/348.000; 435/358.000; 435/360.000; 435/365.100; 435/366.000; 536/023.500 NCL NCLM: 435/069.100 NCLS: 435/070.100; 435/070.300; 435/071.100; 435/071.200; 435/172.300; 435/252.300; 435/252.330; 435/320.100; 435/325.000; 435/348.000; 435/358.000; 435/360.000; 435/365.100; 435/366.000; 536/023.500 IC [6] ICM: C12N005-10 ICS: C12N015-12; C12N015-63; C07H021-04 EXF 435/69.1; 435/240.2; 435/320.1; 435/252.3; 435/252.33; 435/70.1; 435/70.3; 435/71.1; 435/71.2; 435/172.3; 536/23.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 73 USPATFULL  
AN 97:63766 USPATFULL  
TI Methods for in vivo delivery of nutriceuticals and compositions useful therefor

IN Grinstaff, Mark W., Pasadena, CA,  
United States  
Soon-Shiong, Patrick, Los Angeles, CA,  
United States  
Wong, Michael, Champagne, IL, United  
States  
Sandford, Paul A., Los Angeles, CA,  
United States  
Suslick, Kenneth S., Champagne, IL,  
United States  
Desai, Neil P., Los Angeles, CA,  
United States  
PA Vivox Pharmaceuticals, Inc., Santa  
Monica, CA, United States  
(U.S. corporation)  
PI US 5650156 970722  
AI US 95-482272 950607 (8)  
RLI Continuation-in-part of Ser. No. US  
94-200235, filed on 22 Feb  
1994, now patented, Pat. No. US  
5498421 which is a  
continuation-in-part of Ser. No. US  
93-23698, filed on 22 Feb  
1993, now patented, Pat. No. US  
5439686 And Ser. No. US 93-35150,  
filed on 26 Mar 1993, now patented,  
Pat. No. US 5362478  
DT Utility  
LN.CNT 3310  
INCL INCLM: 424/400.000  
INCLS: 424/450.000; 424/451.000;  
424/056.000; 424/009.400;  
424/009.500; 424/009.300  
NCL NCLM: 424/400.000  
NCLS: 424/009.300; 424/009.400;  
424/009.500; 424/056.000;  
424/450.000; 424/451.000  
IC [6]  
ICM: A61K009-00  
EXF 424/400; 424/450; 424/451; 424/9  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L6 ANSWER 37 OF 73 USPATFULL  
AN 97:61667 USPATFULL  
TI Methods of treatment using ciliary  
neurotrophic factor  
IN Davis, Samuel, New York, NY, United  
States  
Squinto, Stephen P., Irvington, NY,  
United States  
Furth, Mark E., Pelham, NY, United  
States  
Yancopoulos, George D., Briarcliff  
Manor, NY, United States  
PA Regeneron Pharmaceuticals, Inc.,  
Tarrytown, NY, United States  
(U.S. corporation)  
PI US 5648334 970715  
AI US 95-449329 950524 (8)  
RLI Division of Ser. No. US 93-1904, filed  
on 7 Jan 1993, now  
abandoned which is a continuation of  
Ser. No. US 91-700677, filed  
on 15 May 1991, now abandoned which is  
a continuation-in-part of  
Ser. No. US 91-676647, filed on 28 Mar  
1991, now patented, Pat.  
No. US 5426177 which is a  
continuation-in-part of Ser. No. US  
90-532285, filed on 1 Jun 1990, now  
abandoned  
DT Utility  
LN.CNT 2326  
INCL INCLM: 514/012.000

INCLS: 514/002.000; 530/350.000;  
530/399.000  
NCL NCLM: 514/012.000  
NCLS: 514/002.000; 530/350.000;  
530/399.000  
IC [6]  
ICM: A61K038-17  
ICS: C07K014-475  
EXF 514/2; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L6 ANSWER 38 OF 73 USPATFULL  
AN 97:54233 USPATFULL  
TI Substituted amino alcohol compounds  
IN Klein, J. Peter, Vashon, WA, United  
States  
Underiner, Gail E., Brier, WA, United  
States  
Kumar, Anil M., Seattle, WA, United  
States  
PA Cell Therapeutics, Inc., Seattle, WA,  
United States (U.S.  
corporation)  
PI US 5641783 970624  
AI US 94-303842 940908 (8)  
RLI Continuation-in-part of Ser. No. US  
93-152650, filed on 12 Nov  
1993 And Ser. No. US 93-164081, filed  
on 8 Dec 1993, now patented,  
Pat. No. US 5470878  
DT Utility  
LN.CNT 3206  
INCL INCLM: 514/263.000  
INCLS: 514/183.000; 514/222.500;  
514/223.500; 514/224.200;  
514/226.800; 514/227.500;  
514/228.800; 514/229.200;  
514/230.500; 514/230.800;  
514/237.800; 514/241.000;  
514/242.000; 514/243.000;  
514/246.000; 514/247.000;  
514/248.000; 514/249.000;  
514/255.000; 514/256.000;  
514/258.000; 514/259.000;  
514/261.000; 514/262.000;  
514/263.000; 514/270.000;  
514/274.000; 514/297.000;  
514/300.000; 514/301.000;  
514/302.000; 514/303.000;  
514/306.000; 514/307.000;  
514/311.000; 514/312.000;  
514/315.000; 514/345.000;  
514/351.000; 514/357.000;  
514/359.000; 514/360.000;  
514/361.000; 514/362.000;  
514/363.000; 514/364.000;  
514/365.000; 514/367.000;  
514/369.000; 514/372.000;  
514/373.000; 514/374.000;  
514/375.000; 514/376.000;  
514/378.000; 514/379.000;  
514/380.000; 514/381.000;  
514/383.000; 514/389.000;  
514/394.000; 514/395.000;  
514/398.000; 514/399.000;  
514/401.000; 514/404.000;  
514/406.000; 514/413.000;  
514/415.000; 514/416.000;  
514/418.000; 514/423.000;  
514/424.000; 514/425.000;  
514/427.000; 514/428.000;  
544/001.000; 544/002.000;  
544/003.000; 544/008.000;  
544/053.000; 544/063.000;  
544/065.000; 544/066.000;

544/091.000; 544/162.000;  
544/219.000; 544/220.000;  
544/239.000; 544/254.000;  
544/262.000; 544/272.000;  
544/280.000; 544/283.000;  
544/311.000; 544/335.000;  
544/353.000; 544/385.000;  
546/113.000; 546/114.000;  
546/118.000; 546/119.000;  
546/139.000; 546/150.000;  
546/164.000; 546/176.000;  
546/243.000; 546/246.000;  
546/334.000; 548/100.000;  
548/127.000; 548/128.000;  
548/146.000; 548/153.000;  
548/207.000; 548/214.000;  
548/221.000; 548/225.000;  
548/235.000; 548/237.000;  
548/243.000; 548/247.000;  
548/267.800; 548/303.700;  
548/309.700; 548/319.100;  
548/348.100; 548/349.100;  
548/375.100; 548/379.400;  
548/470.000; 548/482.000;  
548/491.000; 548/503.000;  
548/546.000; 548/550.000;  
NCL NCLM: 514/263.000  
NCLS: 514/183.000; 514/222.500;  
514/223.500; 514/224.200;  
514/228.800; 514/229.200;  
514/237.800; 514/241.000;  
514/246.000; 514/247.000;  
514/255.000; 514/256.000;  
514/261.000; 514/262.000;  
514/297.000; 514/300.000;  
514/303.000; 514/306.000;  
514/312.000; 514/315.000;  
514/357.000; 514/359.000;  
514/362.000; 514/363.000;  
514/367.000; 514/369.000;  
514/374.000; 514/375.000;  
514/379.000; 514/380.000;  
514/389.000; 514/394.000;  
514/399.000; 514/401.000;  
514/413.000; 514/415.000;  
514/423.000; 514/424.000;  
514/428.000; 544/001.000;  
544/008.000; 544/053.000;  
544/066.000; 544/067.000;  
544/162.000; 544/215.000;  
544/220.000; 544/235.000;  
544/239.000; 544/254.000;  
544/255.000; 544/257.000;  
544/272.000; 544/277.000;  
544/283.000; 544/286.000;  
544/301.000; 544/306.000;  
544/335.000; 544/336.000;  
544/350.000; 544/353.000;  
544/380.000; 544/381.000;  
544/383.000; 544/394.000;  
544/398.000; 544/395.000;  
514/404.000; 514/406.000;  
514/416.000; 514/418.000;  
514/424.000; 514/425.000;  
514/427.000; 514/428.000;  
544/002.000; 544/003.000;  
544/053.000; 544/063.000;  
544/065.000; 544/066.000;  
544/090.000; 544/091.000;  
544/215.000; 544/216.000;  
544/219.000; 544/220.000;  
544/224.000; 544/235.000;  
544/255.000; 544/257.000;  
544/277.000; 544/278.000;  
544/280.000; 544/283.000;  
544/286.000; 544/301.000;  
544/336.000; 544/350.000;  
544/353.000; 544/385.000;  
544/401.000; 546/102.000;  
546/115.000; 546/117.000;  
546/118.000; 546/119.000;  
546/150.000; 546/153.000;  
546/176.000; 546/178.000;  
546/242.000; 546/246.000;  
546/300.000; 546/264.000;  
548/100.000; 548/123.000;  
548/125.000; 548/128.000;  
548/131.000; 548/134.000;  
548/153.000; 548/179.000;  
548/186.000; 548/207.000;  
548/214.000; 548/215.000;  
548/217.000; 548/225.000;  
548/228.000; 548/229.000;  
548/237.000; 548/240.000;  
548/241.000; 548/247.000;  
548/267.200; 548/252.000;  
548/303.700; 548/267.800;  
548/306.400; 548/307.100;  
548/319.100; 548/319.100;  
548/323.500; 548/340.100;  
548/349.100; 548/356.100;  
548/379.400; 548/452.000;  
548/453.000; 548/485.000;  
548/486.000; 548/482.000;  
548/491.000; 548/503.000;  
548/532.000; 548/543.000;  
548/550.000; 548/565.000;  
548/566.000; 548/565.000;  
548/566.000; 548/566.000;  
548/122.000; 548/123.000;  
548/127.000; 548/125.000;  
548/131.000; 548/134.000;  
548/146.000; 548/153.000;  
548/153.000; 548/157.000;  
548/178.000; 546/176.000;  
548/242.000; 546/246.000;  
548/264.000; 546/300.000;  
548/123.000; 548/125.000;  
548/127.000; 548/128.000;  
548/131.000; 548/134.000;  
548/146.000; 548/153.000;  
548/153.000; 548/179.000;  
548/215.000; 548/214.000;  
548/221.000; 548/225.000;  
548/228.000; 548/237.000;  
548/241.000; 548/240.000;  
548/243.000; 548/247.000;  
548/252.000; 548/252.000;  
548/267.800; 548/267.200;  
548/306.400; 548/303.700;  
548/307.100; 548/309.700;  
548/323.500; 548/349.100;  
548/340.100; 548/349.100;  
548/356.100; 548/349.100;  
548/370.100; 548/379.400;  
548/452.000; 548/482.000;  
548/453.000; 548/485.000;  
548/470.000; 548/482.000;  
548/486.000; 548/482.000;  
548/491.000; 548/503.000;  
548/532.000; 548/532.000;  
548/543.000; 548/546.000;  
548/565.000; 548/550.000;  
548/566.000; 548/550.000;

IC [6]  
ICM: A61K031-415  
ICS: A61K031-42; A61K031-425; A61K031-  
52  
EXF 544/272; 514/263  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 73 USPATFULL  
AN 97:54200 USPATFULL  
TI Methods for treating photoreceptors  
using glial cell line-derived  
neurotrophic factor (GDNF) protein  
product  
IN Louis, Jean-Claude, Thousand Oaks, CA,  
United States  
PA Amgen Inc., Thousand Oaks, CA, United  
States (U.S. corporation)  
PI US 5641750 970624  
AI US 95-564833 951129 (8)  
DT Utility  
LN.CNT 2005  
INCL INCLM: 514/012.000  
INCLS: 435/069.100; 435/069.400  
NCL NCLM: 514/012.000  
NCLS: 435/069.100; 435/069.400  
IC [6]  
ICM: A61F002-00  
ICS: A61K047-00; A61K031-685  
EXF 514/12; 435/69.1; 435/69.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> file caplus medline

COST IN U.S. DOLLARS  
SINCE FILE TOTAL

ENTRY SESSION  
FULL ESTIMATED COST  
83.65 121.60

FILE 'CAPLUS' ENTERED AT 20:21:20 ON 26 APR  
1998  
USE IS SUBJECT TO THE TERMS OF YOUR STN  
CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY  
(ACS)

FILE 'MEDLINE' ENTERED AT 20:21:20 ON 26 APR  
1998

=> s 14

L7 53 L4

=> e ishii d/au

E1 7 ISHII CHIZU/AU  
E2 1 ISHII CLIFF/AU  
E3 87 --> ISHII D/AU  
E4 57 ISHII D N/AU  
E5 227 ISHII DAIDO/AU  
E6 1 ISHII DEISUKE/AU  
E7 1 ISHII DOUBLAS N/AU  
E8 2 ISHII DOUGLAS/AU  
E9 39 ISHII DOUGLAS N/AU  
E10 134 ISHII E/AU  
E11 3 ISHII E K/AU  
E12 7 ISHII E L/AU

=> s (e3-4 or e7-9) and igf?

L8 43 ((ISHII D/AU OR "ISHII D  
N"/AU) OR ("ISHII DOUBLAS N"/AU

OR "ISHII DOUGLAS"/AU OR  
"ISHII DOUGLAS N"/AU) AND IGF?

=> d 1-43

L8 ANSWER 1 OF 43 CAPLUS COPYRIGHT 1998  
ACS  
AN 1997:674681 CAPLUS  
DN 127:342187  
TI Insulin-like growth factor (IGF) gene  
expression is  
reduced in neural tissues and liver from  
rats with  
non-insulin-dependent diabetes mellitus,  
and IGF treatment  
ameliorates diabetic neuropathy  
AU Zhuang, Hui-Xin; Wuarin, Laura; Fei,  
Zhi-Jian; Ishii, Douglas  
N.  
CS Department of Physiology and Department  
of Biochemistry and  
Molecular Biology, Colorado State  
University, Fort Collins, CO, USA  
SO J. Pharmacol. Exp. Ther. (1997), 283(1),  
366-374  
CODEN: JPETAB; ISSN: 0022-3565  
PB Williams & Wilkins  
DT Journal  
LA English

L8 ANSWER 2 OF 43 CAPLUS COPYRIGHT 1998  
ACS  
AN 1997:511653 CAPLUS  
DN 127:104818  
TI Method for effecting changes in the  
central nervous system by  
administration of IGF-I or IGF-II  
IN Ishii, Douglas N.  
PA Colorado State University Research  
Foundation, USA  
SO PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
PI WO 9721449 A1 970619  
DS W: CA, CN, JP, PL  
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB,  
GR, IE, IT, LU, MC, NL, PT,  
SE  
AI WO 96-US19663 961211  
PRAI US 95-571802 951213  
DT Patent  
LA English

L8 ANSWER 3 OF 43 CAPLUS COPYRIGHT 1998  
ACS  
AN 1997:371022 CAPLUS  
DN 127:60676  
TI Roles of insulin-like growth factors in  
peripheral nerve  
regeneration and motor neuron survival  
AU Ishii, D. N.; Pu, S. F.; Glazner, G. W.;  
Zhuang, H.-X.;  
Marsh, D. J.  
CS Department Physiology, Department  
Biochemistry Molecular Biology,  
Colorado State University, Fort Collins,  
CO, 80523, USA  
SO Chem. Factors Neural Growth, Degener.  
Repair (1996), 399-421.  
Editor(s): Bell, Christopher. Publisher:  
Elsevier, Amsterdam, Neth.  
CODEN: 64MUAK  
DT Conference; General Review  
LA English

L8 ANSWER 4 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1996:511170 CAPLUS  
 DN 125:186579  
 TI Insulin-like growth factors reverse or arrest diabetic neuropathy:  
     Effects on hyperalgesia and impaired nerve regeneration in rats  
 AU Zhuang, Hui-Xin; Snyder, Cynthia K.; Pu, Su-Fen; **Ishii, Douglas N.**  
 CS Department Physiology, Colorado State University, Fort Collins, CO, 80523, USA  
 SO Exp. Neurol. (1996), 140(2), 198-205  
 CODEN: EXNEAC; ISSN: 0014-4886  
 DT Journal  
 LA English

L8 ANSWER 5 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1996:454059 CAPLUS  
 DN 125:139592  
 TI Brain insulin-like growth factor-II mRNA content is reduced in insulin-dependent and non-insulin-dependent diabetes mellitus  
 AU Wuarin, Laura; Namdev, Ritu; Burns, J. Gregory; Fei, Zhi-Jian; **Ishii, Douglas N.**  
 CS Departments of Physiology and Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, 80523, USA  
 SO J. Neurochem. (1996), 67(2), 742-751  
 CODEN: JONRA9; ISSN: 0022-3042  
 DT Journal  
 LA English

L8 ANSWER 6 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1995:934824 CAPLUS  
 DN 124:1406  
 TI Differential spatio-temporal expression of the insulin-like growth factor genes in regenerating sciatic nerve  
 AU Pu, Su-Fen; Zhuang, Hui-Xin; **Ishii, Douglas N.**  
 CS Department of Physiology and Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, 80523, USA  
 SO Mol. Brain Res. (1995), 34(1), 18-28  
 CODEN: MBREE4; ISSN: 0169-328X  
 DT Journal  
 LA English

L8 ANSWER 7 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1995:386789 CAPLUS  
 DN 122:184587  
 TI Early reduction in insulin-like growth factor gene expression in diabetic nerve  
 AU Wuarin, Laura; Guertin, Diane M.; **Ishii, Douglas N.**  
 CS Department of Physiology, Colorado State University, Fort Collins, CO, 80523, USA  
 SO Exp. Neurol. (1994), 130(1), 106-14  
 CODEN: EXNEAC; ISSN: 0014-4886

DT Journal  
 LA English

L8 ANSWER 8 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1995:323050 CAPLUS  
 DN 122:97171  
 TI Insulin-like growth factors protect against diabetic neuropathy:  
     effects on sensory nerve regeneration in rats  
 AU **Ishii, D. N.**; Lupien, S. B.  
 CS Departments Physiol. Biochem. Mol. Biol., Colorado State Univ., Fort Collins, CO, USA  
 SO J. Neurosci. Res. (1995), 40(1), 138-44  
 CODEN: JNREDK; ISSN: 0360-4012  
 DT Journal  
 LA English

L8 ANSWER 9 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1995:235660 CAPLUS  
 DN 122:7052  
 TI Reduced insulin-like growth factor-I mRNA content in liver, adrenal glands and spinal cord of diabetic rats  
 AU **Ishii, D.N.**; Guertin, D.M.; Whalen, L.R.  
 CS Department of Physiology, Colorado State University, Fort Collins, CO, 80523, USA  
 SO Diabetologia (1994), 37(11), 1073-81  
 CODEN: DBTG AJ; ISSN: 0012-186X  
 DT Journal  
 LA English

L8 ANSWER 10 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1994:622051 CAPLUS  
 DN 121:222051  
 TI Role of insulin-like growth factors in peripheral nerve regeneration  
 AU **Ishii, D. N.**; Glazner, G. W.; Pu, S.-F.  
 CS Department of Physiology, Colorado State University, Fort Collins, CO, 80523, USA  
 SO Pharmacol. Ther. (1994), 62(1-2), 125-44  
 CODEN: PHTHDT; ISSN: 0163-7258  
 DT Journal; General Review  
 LA English

L8 ANSWER 11 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1994:596717 CAPLUS  
 DN 121:196717  
 TI Elevated insulin-like growth factor (IGF) gene expression in sciatic nerves during IGF-supported nerve regeneration  
 AU Glazner, Gordon W.; Morrison, Andrew E.; **Ishii, Douglas N.**  
 CS Department of Physiology and, Fort Collins, CO, 80523, USA  
 SO Mol. Brain Res. (1994), 25(3-4), 265-72  
 CODEN: MBREE4; ISSN: 0169-328X  
 DT Journal  
 LA English

L8 ANSWER 12 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1993:662607 CAPLUS  
 DN 119:262607  
 TI Regulation of peripheral nerve regeneration by insulin-like growth

factors  
 AU Ishii, Douglas N.; Glazner, Gordon W.;  
 Whalen, L. Raymond  
 CS Dep. Physiol., Colorado State Univ., Fort  
 Collins, CO, 80523, USA  
 SO Ann. N. Y. Acad. Sci. (1993), 692(Role  
 of Insulin-like Growth  
 Factors in the Nervous System), 172-82  
 CODEN: ANYAA9; ISSN: 0077-8923  
 DT Journal; General Review  
 LA English

L8 ANSWER 13 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1993:487255 CAPLUS  
 DN 119:87255  
 TI Insulin-like growth factor II increases  
 the rate of sciatic nerve  
 regeneration in rats  
 AU Glazner, G. W.; Lupien, S.; Miller, J.  
 A.; Ishii, D. N.  
 CS Dep. Physiol., Colorado State Univ.,  
 Fort Collins, CO, 80523, USA  
 SO Neuroscience (Oxford) (1993), 54(3),  
 791-7  
 CODEN: NRSCDN; ISSN: 0306-4522  
 DT Journal  
 LA English

L8 ANSWER 14 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1993:183474 CAPLUS  
 DN 118:183474  
 TI Neurobiology of insulin and insulin-like  
 growth factors  
 AU Ishii, Douglas N.  
 CS Dep. Physiol., Colorado State Univ.,  
 Fort Collins, CO, 80523, USA  
 SO Neurotrophic Factors (1993), 415-42.  
 Editor(s): Loughlin, Sandra  
 E.; Fallon, James H. Publisher:  
 Academic, San Diego, Calif.  
 CODEN: 58VKAI  
 DT Conference; General Review  
 LA English

L8 ANSWER 15 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1993:74365 CAPLUS  
 DN 118:74365  
 TI Insulin-like growth factor II stimulates  
 motor nerve regeneration  
 AU Near, Stephanie L.; Whalen, L. Raymond;  
 Miller, James A.;  
 Ishii, Douglas N.  
 CS Dep. Anat. Neurobiol., Colorado State  
 Univ., Fort Collins, CO,  
 80523, USA  
 SO Proc. Natl. Acad. Sci. U. S. A. (1992),  
 89(24), 11716-20  
 CODEN: PNASA6; ISSN: 0027-8424  
 DT Journal  
 LA English

L8 ANSWER 16 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1992:421120 CAPLUS  
 DN 117:21120  
 TI Effects of insulin and insulin-like  
 growth factors on neurofilament  
 mRNA and tubulin mRNA content in human  
 neuroblastoma SH-SY5Y cells  
 AU Wang, C.; Li, Y.; Wible, B.; Angelides,  
 K. J.; Ishii, D. N.

CS Dep. Physiol., Colorado State Univ.,  
 Fort Collins, CO, 80523, USA  
 SO Mol. Brain Res. (1992), 13(4), 289-300  
 CODEN: MBREE4; ISSN: 0169-328X  
 DT Journal  
 LA English

L8 ANSWER 17 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1992:99392 CAPLUS  
 DN 116:99392  
 TI Second messengers mediating gene  
 expression essential to neurite  
 formation directed by insulin and  
 insulin-like growth factors  
 AU Ishii, Douglas N.; Wang, Chiang; Li, Yi  
 CS Physiol. Dep., Colorado State Univ.,  
 Fort Collins, CO, 80523, USA  
 SO Adv. Exp. Med. Biol. (1991), 293(Mol.  
 Biol. Physiol. Insulin  
 Insulin-Like Growth Factors), 361-78  
 CODEN: AEMBAP; ISSN: 0065-2598  
 DT Journal; General Review  
 LA English

L8 ANSWER 18 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1990:16837 CAPLUS  
 DN 112:16837  
 TI Stabilization of tubulin mRNAs by  
 insulin and insulin-like growth  
 factor I during neurite formation  
 AU Fernyhough, P.; Mill, J. F.; Roberts, J.  
 L.; Ishii, D. N.  
 CS Dep. Physiol., Colorado State Univ.,  
 Fort Collins, CO, 80523, USA  
 SO Mol. Brain Res. (1989), 6(2-3), 109-20  
 CODEN: MBREE4; ISSN: 0169-328X  
 DT Journal  
 LA English

L8 ANSWER 19 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1989:206568 CAPLUS  
 DN 110:206568  
 TI Relationship of insulin-like growth  
 factor II gene expression in  
 muscle to synaptogenesis  
 AU Ishii, Douglas N.  
 CS Dep. Physiol., Colorado State Univ.,  
 Fort Collins, CO, 80523, USA  
 SO Proc. Natl. Acad. Sci. U. S. A. (1989),  
 86(8), 2898-702  
 CODEN: PNASA6; ISSN: 0027-8424  
 DT Journal  
 LA English

L8 ANSWER 20 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1988:448522 CAPLUS  
 DN 109:48522  
 TI Insulin and related growth factors:  
 effects on the nervous system  
 and mechanism for neurite growth and  
 regeneration  
 AU Recio-Pinto, E.; Ishii, D. N.  
 CS Med. Cent., Cornell Univ., New York, NY,  
 10021, USA  
 SO Neurochem. Int. (1988), 12(4), 397-414  
 CODEN: NEUIDS; ISSN: 0197-0186  
 DT Journal; General Review  
 LA English

L8 ANSWER 21 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1988:198730 CAPLUS  
 DN 108:198730  
 TI Insulin and insulinlike growth factor receptors regulating neurite formation in cultured human neuroblastoma cells  
 AU Recio-Pinto, E.; **Ishii, Douglas N.**  
 CS Med. Coll., Cornell Univ., New York, NY, USA  
 SO J. Neurosci. Res. (1988), 19(3), 312-20  
 CODEN: JNREDK; ISSN: 0360-4012  
 DT Journal  
 LA English

L8 ANSWER 22 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1987:150522 CAPLUS  
 DN 106:150522  
 TI Rat insulin-like growth factor II gene. A single gene with two promoters expressing a multitranscript family  
 AU Soares, Marcelo Bento; Turken, Arthur; **Ishii, Douglas;**  
 Mills, Leslie; Episkopou, Vasso; Cotter, Sean; Zeitlin, Scott; Efstratiadis, Argiris  
 CS Dep. Genet. Dev., Columbia Univ., New York, NY, 10032, USA  
 SO J. Mol. Biol. (1986), 192(4), 737-52  
 CODEN: JMOBAK; ISSN: 0022-2836  
 DT Journal  
 LA English

L8 ANSWER 23 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1986:455253 CAPLUS  
 DN 105:55253  
 TI Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons  
 AU Recio-Pinto, Esperanza; Rechler, Matthew M.; **Ishii, Douglas N.**  
 CS Lab. Biochem. Pharmacol., Natl. Inst. Arthritis, Metabol., Dig. Dis., Bethesda, MD, 20205, USA  
 SO J. Neurosci. (1986), 6(5), 1211-9  
 CODEN: JNRSDS; ISSN: 0270-6474  
 DT Journal  
 LA English

L8 ANSWER 24 OF 43 CAPLUS COPYRIGHT 1998  
 ACS  
 AN 1984:433669 CAPLUS  
 DN 101:33669  
 TI Effects of insulin, insulin-like growth factor-II and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells  
 AU Recio-Pinto, Esperanza; **Ishii, Douglas N.**  
 CS Coll. Phys. Surg., Columbia Univ., New York, NY, 10032, USA  
 SO Brain Res. (1984), 302(2), 323-34  
 CODEN: BRREAP; ISSN: 0006-8993  
 DT Journal  
 LA English

L8 ANSWER 25 OF 43 MEDLINE

AN 97476094 MEDLINE  
 DN 97476094  
 TI Insulin-like growth factor (IGF) gene expression is reduced in neural tissues and liver from rats with non-insulin-dependent diabetes mellitus, and IGF treatment ameliorates diabetic neuropathy.  
 AU Zhuang H X; Wuarin L; Fei Z J; **Ishii D N**  
 CS Department of Physiology, Colorado State University, Fort Collins 80523, USA.  
 NC R01-DK539222 (NIDDK)  
 SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1997 Oct) 283 (1) 366-74.  
 Journal code: JP3. ISSN: 0022-3565.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199801  
 EW 19980104

L8 ANSWER 26 OF 43 MEDLINE  
 AN 96363028 MEDLINE  
 DN 96363028  
 TI Differential spatio-temporal expression of the insulin-like growth factor genes in regenerating sciatic nerve.  
 AU Pu S F; Zhuang H X; **Ishii D N**  
 CS Department of Physiology, Colorado State University, Fort Collins 80523, USA.  
 NC P01 NS28323 (NINDS)  
 SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1995 Dec 1) 34 (1) 18-28.  
 Journal code: MBR. ISSN: 0169-328X.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199703  
 EW 19970303

L8 ANSWER 27 OF 43 MEDLINE  
 AN 96340157 MEDLINE  
 DN 96340157  
 TI Brain insulin-like growth factor-II mRNA content is reduced in insulin-dependent and non-insulin-dependent diabetes mellitus.  
 AU Wuarin L; Namdev R; Burns J G; Fei Z J; **Ishii D N**  
 CS Department of Physiology, Colorado State University, Fort Collins 805231, USA.  
 NC R01 NS24327 (NINDS)  
 SO JOURNAL OF NEUROCHEMISTRY, (1996 Aug) 67 (2) 742-51.  
 Journal code: JAV. ISSN: 0022-3042.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199611

L8 ANSWER 28 OF 43 MEDLINE  
 AN 96309674 MEDLINE  
 DN 96309674  
 TI Insulin-like growth factors reverse or arrest diabetic neuropathy:

effects on hyperalgesia and impaired nerve regeneration in rats.

AU Zhuang H X; Snyder C K; Pu S F; Ishii D N  
 CS Department of Physiology, Colorado State University, Fort Collins 80523, USA.

NC RO1 NS 24327 (NINDS)  
 SO EXPERIMENTAL NEUROLOGY, (1996 Aug) 140 (2) 198-205.  
 Journal code: EQF. ISSN: 0014-4886.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199610

L8 ANSWER 29 OF 43 MEDLINE  
 AN 96074488 MEDLINE  
 DN 96074488  
 TI Insulinlike growth factor gene expression in rat muscle during reinnervation.

AU Glazner G W; Ishii D N  
 CS Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins 80523, USA..

NC PO1 NS28323 (NINDS)  
 SO MUSCLE AND NERVE, (1995 Dec) 18 (12) 1433-42.  
 Journal code: NN9. ISSN: 0148-639X.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199602

L8 ANSWER 30 OF 43 MEDLINE  
 AN 95230709 MEDLINE  
 DN 95230709  
 TI Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats.

AU Ishii D N; Lupien S B  
 CS Department of Physiology, Colorado State University, Fort Collins 80523..

NC RO1 NS23427 (NINDS)  
 SO JOURNAL OF NEUROSCIENCE RESEARCH, (1995 Jan 1) 40 (1) 138-44.  
 Journal code: KAC. ISSN: 0360-4012.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199507

L8 ANSWER 31 OF 43 MEDLINE  
 AN 95227210 MEDLINE  
 DN 95227210  
 TI Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy.

AU Ishii D N  
 CS Department of Physiology, Colorado State University, Fort Collins 80523, USA..

NC RO1NS24327 (NINDS)  
 SO BRAIN RESEARCH. BRAIN RESEARCH REVIEWS, (1995 Jan) 20 (1) 47-67.  
 Ref: 239  
 Journal code: BRS. ISSN: 0165-0173.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199507

L8 ANSWER 32 OF 43 MEDLINE  
 AN 95172323 MEDLINE  
 DN 95172323  
 TI Reduced insulin-like growth factor-I mRNA content in liver, adrenal glands and spinal cord of diabetic rats.

AU Ishii D N; Guertin D M; Whalen L R  
 CS Department of Physiology, Colorado State University, Fort Collins 80523..

NC RO1 NS24327 (NINDS)  
 SO DIABETOLOGIA, (1994 Nov) 37 (11) 1073-81.  
 Journal code: E93. ISSN: 0012-186X.

CY GERMANY: Germany, Federal Republic of  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199506

L8 ANSWER 33 OF 43 MEDLINE  
 AN 95121409 MEDLINE  
 DN 95121409  
 TI Early reduction in insulin-like growth factor gene expression in diabetic nerve.

AU Wuarin L; Guertin D M; Ishii D N  
 CS Department of Physiology, Colorado State University, Fort Collins 80523..

NC RO1 NS24327 (NINDS)  
 SO EXPERIMENTAL NEUROLOGY, (1994 Nov) 130 (1) 106-14.  
 Journal code: EQF. ISSN: 0014-4886.

CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199504

L8 ANSWER 34 OF 43 MEDLINE  
 AN 95107044 MEDLINE  
 DN 95107044  
 TI Elevated insulin-like growth factor (IGF) gene expression in sciatic nerves during IGF-supported nerve regeneration.

AU Glazner G W; Morrison A E; Ishii D N  
 CS Department of Physiology, Colorado State University, Fort Collins 80523.

NC PO1 NS28323 (NINDS)  
 SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1994 Sep) 25 (3-4) 265-72.  
 Journal code: MBR. ISSN: 0169-328X.

CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199504

L8 ANSWER 35 OF 43 MEDLINE  
 AN 95083707 MEDLINE  
 DN 95083707  
 TI Role of insulin-like growth factors in peripheral nerve

regeneration.

AU **Ishii D N**; Glazner G W; Pu S F  
CS Department of Physiology, Colorado State University, Fort Collins 80523..

NC 1P01 NS28323 (NINDS)  
SO PHARMACOLOGY AND THERAPEUTICS, (1994 Apr-May) 62 (1-2) 125-44. Ref: 135  
Journal code: P44. ISSN: 0163-7258.

CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE) General Review; (REVIEW, TUTORIAL)  
LA English  
FS Priority Journals  
EM 199503

L8 ANSWER 36 OF 43 MEDLINE  
AN 93101597 MEDLINE  
DN 93101597  
TI Insulin-like growth factor II stimulates motor nerve regeneration.

AU Near S L; Whalen L R; Miller J A; **Ishii D N**  
CS Department of Anatomy and Neurobiology, Colorado State University, Fort Collins 80523..

NC RO1 NS24787 (NINDS)  
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1992 Dec 15) 89 (24) 11716-20.  
Journal code: PV3. ISSN: 0027-8424.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals; Cancer Journals  
EM 199303

L8 ANSWER 37 OF 43 MEDLINE  
AN 92326572 MEDLINE  
DN 92326572  
TI Effects of insulin and insulin-like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-SY5Y cells.

AU Wang C; Li Y; Wible B; Angelides K J; **Ishii D N**  
CS Department of Physiology, Colorado State University, Fort Collins 80523..

NC P01 NS28323 (NINDS)  
RO1 NS24787 (NINDS)  
NS26733 (NINDS)  
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1992 May) 13 (4) 289-300.  
Journal code: MBR. ISSN: 0169-328X.

CY Netherlands  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199210

L8 ANSWER 38 OF 43 MEDLINE  
AN 90135914 MEDLINE  
DN 90135914  
TI Stabilization of tubulin mRNAs by insulin and insulin-like growth factor I during neurite formation.

AU Fernyough P; Mill J F; Roberts J L; **Ishii D N**  
CS Department of Physiology, Colorado State University, Fort Collins

80523.  
NC RO1 NS 24327 (NINDS)  
SO BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH, (1989 Nov) 6 (2-3) 109-20.  
Journal code: MBR. ISSN: 0169-328X.

CY Netherlands  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199005

L8 ANSWER 39 OF 43 MEDLINE  
AN 89202433 MEDLINE  
DN 89202433  
TI Relationship of insulin-like growth factor II gene expression in muscle to synaptogenesis.

AU **Ishii D N**  
CS Department of Physiology, Colorado State University, Fort Collins 80523..

NC RO1 NS24787 (NINDS)  
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1989 Apr) 86 (8) 2898-902.  
Journal code: PV3. ISSN: 0027-8424.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals; Cancer Journals  
EM 198907

L8 ANSWER 40 OF 43 MEDLINE  
AN 88245201 MEDLINE  
DN 88245201  
TI Insulin and insulinlike growth factor receptors regulating neurite formation in cultured human neuroblastoma cells.

AU Recio-Pinto E; **Ishii D N**  
CS Department of Anesthesiology, Medical College, Cornell University, New York, New York.

NC RO1 NS24787 (NINDS)  
SO JOURNAL OF NEUROSCIENCE RESEARCH, (1988 Mar) 19 (3) 312-20.  
Journal code: KAC. ISSN: 0360-4012.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 198809

L8 ANSWER 41 OF 43 MEDLINE  
AN 87226166 MEDLINE  
DN 87226166  
TI Rat insulin-like growth factor II gene. A single gene with two promoters expressing a multitranscript family.

AU Soares M B; Turken A; **Ishii D**; Mills L; Episkopou V; Cotter S; Zeitlin S; Efstratiadis A  
SO JOURNAL OF MOLECULAR BIOLOGY, (1986 Dec 20) 192 (4) 737-52.  
Journal code: JMB. ISSN: 0022-2836.

CY ENGLAND: United Kingdom  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals; Cancer Journals  
EM 198709

L8 ANSWER 42 OF 43 MEDLINE  
AN 86226464 MEDLINE

DN 86226464  
 TI Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons.  
 AU Recio-Pinto E; Rechler M M; **Ishii D N**  
 NC R01 AM32841 (NIADDK)  
 SO JOURNAL OF NEUROSCIENCE, (1986 May) 6 (5) 1211-9.  
 Journal code: JDF. ISSN: 0270-6474.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198609

L8 ANSWER 43 OF 43 MEDLINE  
 AN 84233406 MEDLINE  
 DN 84233406  
 TI Effects of insulin, insulin-like growth factor-II and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells.

AU Recio-Pinto E; **Ishii D N**  
 NC R01 NS 14218 (NINDS)  
 R01 AM32841 (NIADDK)  
 1K04 NS 00375 (NINDS)  
 +  
 SO BRAIN RESEARCH, (1984 Jun 8) 302 (2) 323-34.  
 Journal code: B5L. ISSN: 0006-8993.  
 CY Netherlands  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198410

=> file uspatfull

COST IN U.S. DOLLARS  
 SINCE FILE TOTAL

ENTRY SESSION  
 FULL ESTIMATED COST  
 49.22 170.82

FILE 'USPATFULL' ENTERED AT 20:34:45 ON 26 APR 1998  
 CA INDEXING COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE:  
 21 Apr 1998 (19980421/PD)  
 FILE LAST UPDATED: 22 Apr 1998 (19980422/ED)  
 HIGHEST PATENT NUMBER: US5742935  
 CA INDEXING IS CURRENT THROUGH 22 Apr 1998 (19980422/UPCA)  
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH:  
 21 Apr 1998 (19980421/PD)  
 REVISED CLASS FIELDS (/NCL) LAST RELOADED:  
 JAN 1998  
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS  
 ISSUE DATE: Feb 1998

>>> Page images are available for patents from 1/1/95. Current <<<  
 >>> week patent text is typically loaded by Thursday morning and <<<  
 >>> page images are available for display by the end of the day. <<<  
 >>> Image data for the /FA field are available the following week. <<<

>>> Complete CA file indexing for chemical patents (or equivalents) <<<  
 >>> is included in file records. A thesaurus is available for the <<<  
 >>> USPTO Manual of Classifications in the /NCL, /INCL, and /RPCL <<<  
 >>> fields. This thesaurus includes catchword terms from the <<<  
 >>> USPTO/MOC subject headings and subheadings. Thesauri are also <<<  
 >>> available for the WIPO International Patent Classification <<<  
 >>> (IPC) Manuals, editions 1-6, in the /IC1, /IC2, /IC3, /IC4, <<<  
 >>> /IC5, and /IC (/IC6) fields, respectively. The thesauri in <<<  
 >>> the /IC5 and /IC fields include the corresponding catchword <<<  
 >>> terms from the IPC subject headings and subheadings. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e ishii, d/in

E1	2	ISHII YUUKO/IN
E2	4	ISHII YUWA/IN
E3	0 -->	ISHII, D/IN
E4	1	ISHIIDE HIDENORI/IN
E5	7	ISHIIZUMI SEIICHI/IN
E6	1	ISHIJIMA AKIRA/IN
E7	2	ISHIJIMA CHIEKO/IN
E8	8	ISHIJIMA HIROSHI/IN
E9	1	ISHIJIMA HIROYASU/IN
E10	2	ISHIJIMA HISASHI/IN
E11	1	ISHIJIMA ICHIRO/IN
E12	1	ISHIJIMA KEIZO/IN

=> e ishii d/au

E1	2	ISHII CHIHO/AU
E2	1	ISHII CHISEKI/AU
E3	0 -->	ISHII D/AU
E4	2	ISHII DAIDO/AU
E5	2	ISHII DAIROKU/AU
E6	12	ISHII DAISUKE/AU
E7	1	ISHII DECEASED HISAO/AU
E8	1	ISHII DECEASED RYOICHI/AU
E9	13	ISHII EIICHI/AU
E10	3	ISHII EIJI/AU
E11	1	ISHII ETUMI/AU
E12	13	ISHII FUMIAKI/AU